

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Study No.: 110847 (FluAS25-025 PRI)
Title: Observer blind immunogenicity and safety study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A with various doses of adjuvants in adults aged 65 years and above. GSK576389A (FluAS25): GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine. (Flu-1)
Rationale: This study was performed to study the immunogenicity and safety of FluAS vaccine (various formulations) administered in adults aged ≥ 65 years compared to Fluarix vaccine. Additionally, the vaccine safety and immune response in subjects aged ≥ 65 years were compared to those of younger adults aged 18 to 40 years receiving Fluarix vaccine. <i>Fluarix™</i> (Flu-2): GSK Biologicals' licensed influenza vaccine.
Phase: II
Study Period: 08 October 2007 to 10 June 2008.
Study Design: Multi-country, multi-centre, randomized (1:1:1:1:1:1:1:1), observer blind for subjects ≥ 65 years and open for subjects aged between 18-40 years, controlled study with 10 parallel groups.
Centers: Multi-centre study with 31 centers in 4 countries (Germany, Netherlands, Sweden, United Kingdom).
Indication: Immunization against influenza in male and female subjects aged 18-40 years old and ≥ 65 years old.
Treatment: The study groups were as follows: <ul style="list-style-type: none"> AS03 1/1 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 1 AS03 1/2 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 2 AS03 1/4 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 3 AS25 1/1 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 4 AS25 1/2 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 5 AS25 1/4 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 6 AS50 1/2 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 7 AS50 1/4 Group: subjects aged ≥ 65 years received Flu-1 vaccine Formulation 8 Flu_Eld Group: subjects aged ≥ 65 years received Flu-2 vaccine. Flu_Yng Group: subjects aged 18-40 years received Flu-2 vaccine. All vaccines were administered intramuscularly in the deltoid region of the non-dominant arm as a single dose.
Objectives: To identify an optimal formulation of the adjuvanted influenza vaccine compared to Flu-2, given intramuscularly in subjects aged ≥ 65 years old, based on immunogenicity (Geometric mean titers [GMT]) for the 3 vaccine strains 21 days following vaccination. <i>Criteria:</i> A contour plot of the overall desirability was built to identify the region of the experimental domain which had the highest desirability by modelling individual GMT from the adjuvanted influenza vaccine groups and computing 90% confidence interval (CI) lower limits for the estimated GMT ratios (adjuvanted vaccine over Flu-2).
Primary Outcome/Efficacy Variable: <i>Observed variable</i> <ul style="list-style-type: none"> At Day 21, serum haemagglutination-inhibition (HI) antibody titer, against each of the 3 vaccine strains, in the ≥ 65 years groups. <i>Derived variable:</i> <ul style="list-style-type: none"> GMTs of HI antibody titers at Day 21.
Secondary Outcome/Efficacy Variable(s): Safety <ul style="list-style-type: none"> Occurrence, intensity, duration and relationship to vaccination of solicited local and general signs and symptoms during a 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after vaccination, in each group. Occurrence, intensity, duration* and relationship to vaccination of unsolicited adverse events (AEs) during a 21-day follow-up period (i.e. day of vaccination and 20 subsequent days) after vaccination, in each group. Occurrence, intensity, duration* and relationship to vaccination of medically significant conditions‡ prompting emergency room visits, hospitalizations or physician visits and that are not routine visits for physical examination or vaccination, during the entire study period (up to Day 180) in each group. Occurrence and relationship to vaccination of serious adverse (SAEs) events during the entire study period (up to

Day 180) in each group.

*Duration of unsolicited AEs and of medically significant conditions was collected but not analyzed

‡ It was decided to analyze the medically significant conditions as all adverse events that resulted in a medically attended visit.

Humoral immune response

Observed variable

- At Days 0, 21 and 180: serum HI antibody titer, against each of the 3 vaccine strains, in each group.

Derived variables

- GMTs of HI antibody titers at Days 0, 21 and 180
- Seroconversion rates (SCR)* at Days 21 and 180, in each group
- Seroconversion factors (SCF)** at Days 21 and 180, in each group
- Seroprotection rates (SPR)*** at Days 0, 21 and 180, in each group

* Seroconversion rate is defined as the percentage of vaccinees who have either a prevaccination titer $< 1:10$ and a post-vaccination titer $\geq 1:40$ or a pre-vaccination titer $\geq 1:10$ and at least a four-fold increase in post-vaccination titer.

**Seroconversion factor defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.

***Seroprotection rate defined as the percentage of vaccinees with a serum HI titer $\geq 1:40$ that usually is accepted as indicating protection.

Cell-Mediated Immunity (CMI) response (only for subjects enrolled in the CMI subset)

Observed variable

At Day 0, 21 and 180:

- Frequency of cytokine-positive cluster of differentiation 4/8 (CD4/CD8) cells per million (10^6) in tests producing at least 2 different cytokines among cluster of differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), tumor necrotic factor- α (TNF- α) and Interferon- γ (IFN- γ).
- Frequency of cytokine-positive CD4/CD8 cells per 10^6 in tests producing at least CD40L and another signal molecule (IL-2, IFN- γ , TNF- α).
- Frequency of cytokine-positive CD4/CD8 cells per 10^6 in tests producing at least IL-2 and another signal molecule (CD40L, IFN- γ , TNF- α).
- Frequency of cytokine-positive CD4/CD8 cells per 10^6 in tests producing at least IFN- γ and another signal molecule (IL-2, CD40L, TNF- α).
- Frequency of cytokine-positive CD4/CD8 cells per 10^6 in tests producing at least TNF- α and another signal molecule (IL-2, CD40L, IFN- γ).

Derived variables:

- For each test, geometric mean (GM) of specific influenza CD4/CD8 T lymphocytes at Days 0, 21 and 180.

Statistical Methods:

The analyses were performed on the Total Vaccinated cohort, the According-To-Protocol (ATP) cohort for immunogenicity HI, the ATP cohort for immunogenicity CMI, the ATP cohort for analysis of persistence for HI and the ATP cohort for analysis of persistence for CMI.

- The Total Vaccinated cohort included all subjects with study vaccine administered.
- The ATP cohort for immunogenicity HI included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals defined in the protocol up to and including Day 21, who did not meet the elimination criteria up to Day 21, for whom immunogenicity HI data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component at Day 21.
- The ATP cohort of immunogenicity CMI included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals defined in the protocol up to and including Day 21, with no elimination criteria during the study up to Day 21, for whom CMI data were available. This included subjects for whom at least one frequency of cytokine-positive CD4/CD8 results was available at Day 21.
- The ATP cohort for analysis of persistence for HI included all evaluable subjects who met all eligibility criteria, who complied with the procedures defined in the protocol during the entire study period and with the intervals defined in the protocol for Day 180, who did not meet the elimination criteria during the entire study, for whom immunogenicity HI data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component at Day 180.
- The ATP cohort for analysis of persistence for CMI included all evaluable subjects: who met all eligibility criteria, who complied with the procedures defined in the protocol during the entire study period and with the intervals defined in the protocol up to Day 180, who did not meet the elimination criteria during the entire study, for whom

CMI data were available. This included subjects for whom assay results were available for CMI for at least one test at Day 180.

Analysis of Immunogenicity:

The analysis of immunogenicity was performed on the ATP cohort for immunogenicity HI, ATP cohort for immunogenicity CMI, the ATP cohort for analysis of persistence for HI and the ATP cohort for analysis of persistence for CMI.

To identify an optimal formulation of the adjuvanted influenza vaccine compared to Flu_Eld Group 21 days following vaccination, the 90% CI of GMT ratio was computed in the experimental domain (combinations of o/w emulsion dosages and MPL dosages) for each strain. The lower limits were then transformed in a [0,1] desirability. A contour plot of the overall desirability (combining the three strains) was built to identify the region of the experimental domain having the highest desirability, i.e. the region containing the formulations (combination of 1 o/w emulsion dosage and 1 MPL dosage) demonstrating the best immunogenicity on the 3 strains in comparison to Flu-2.

For each group and each antibody, the following parameters were also calculated with 95% CI:

- Seropositivity* rates and GMT at Day 0, Day 21 and Day 180,
- SCR at Day 21 and Day 180,
- SCF at Day 21 and Day 180,
- SPR at Day 0, Day 21 and Day 180

In addition, the frequency of influenza specific cytokine-positive CD4/CD8 T-lymphocytes was summarized (descriptive statistics) for each vaccine group and each strain at Days 0, 21 and 180.

*A seropositive subject is a subject with HI antibody titer $\geq 1:10$.

Analysis of Safety

The analysis was based on the Total Vaccinated cohort.

The percentages of subjects reporting each individual solicited local and general symptom during the 7-day (Days 0-6) solicited follow-up period were tabulated with exact 95% CI for each vaccine group. The same tabulation was performed for grade 3 symptoms and for general symptoms with relationship to vaccination. All local symptoms were considered as related to the study vaccination. The duration of each solicited local and general symptom reported during the 7-day solicited follow-up period was tabulated.

The percentage of subjects with at least one report of unsolicited AEs reported within the 21 days (Days 0-20) after vaccination and classified by the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms was tabulated. The same tabulation was performed for grade 3 AEs and for AEs with a relationship to vaccination.

The percentage of subjects with unsolicited AE that resulted in a medically attended visit classified by MedDRA preferred terms and reported within the 180 days after vaccination was tabulated. The same tabulation was done for grade 3 AE and those with a relationship to vaccination. The occurrence of SAEs during the entire study period was also tabulated according to MedDRA preferred terms.


Study Population: Healthy men or women aged ≥ 65 years or aged 18-40 years at the time of the vaccination, free of an acute aggravation of health status. Women of childbearing potential had to practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and were to continue such precautions for 2 months after completion of the vaccination series. Written informed consent was obtained from the subject before study start.

Active Phase

Number of subjects	AS03 1/4 Group	AS03 1/2 Group	AS03 1/1 Group	AS25 1/4 Group	AS25 1/2 Group	AS25 1/1 Group
Planned, N	200	200	200	200	200	200
Randomized, N (Total Vaccinated cohort)	204	202	202	202	199	198
Completed, n (%)	202 (99.0)	201 (99.5)	201 (99.5)	201 (99.5)	198 (99.5)	198 (100)
Total Number Subjects Withdrawn, n (%)	2 (1.0)	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	0 (0.0)
Withdrawn due to Adverse Events, n (%)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable					
Withdrawn for other reasons, n (%)	2 (1.0)	0 (0.0)	1 (0.5)	1 (0.5)	0 (0.0)	0 (0.0)
Demographics	AS03 1/4 Group	AS03 1/2 Group	AS03 1/1 Group	AS25 1/4 Group	AS25 1/2 Group	AS25 1/1 Group
N (Total Vaccinated cohort)	204	202	202	202	199	198
Females: Males	95:109	109:93	105:97	100:102	89:110	102:96
Mean Age, years (SD)	72.7 (5.75)	72.6 (5.16)	72.4 (5.62)	72.9 (6.09)	72.6 (5.66)	72.7 (5.56)
Caucasian / European heritage, n (%)	199 (97.5)	201 (99.5)	198 (98.0)	199 (98.5)	197 (99.0)	194 (98.0)

Extended Safety Follow-up

Number of subjects	AS03 1/4 Group	AS03 1/2 Group	AS03 1/1 Group	AS25 1/4 Group	AS25 1/2 Group	AS25 1/1 Group
Planned, N	200	200	200	200	200	200
Randomized, N (Total Vaccinated cohort)	204	202	202	202	199	198
Completed, n (%)	200 (98.0)	201 (99.5)	197 (97.5)	197 (97.5)	195 (98.0)	198 (100)
Total Number Subjects Withdrawn, n (%)	4 (2.0)	1 (0.5)	5 (2.5)	5 (2.5)	4 (2.0)	0 (0.0)
Withdrawn due to Adverse Events, n (%)	2 (1.0)	0 (0.0)	1 (0.5)	2 (1.0)	2 (1.0)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable					
Withdrawn for other reasons, n (%)	2 (1.0)	1 (0.5)	4 (2.0)	3 (1.5)	2 (1.0)	0 (0.0)
Active Phase						
Number of subjects	AS50 1/4 Group	AS50 1/2 Group	Flu_Eld Group		Flu_Yng Group	
Planned, N	200	200	200		200	
Randomized, N (Total Vaccinated cohort)	198	199	200		203	
Completed, n (%)	198 (100)	198 (99.5)	199 (99.5)		201 (99.0)	
Total Number Subjects Withdrawn, n (%)	0 (0.0)	1 (0.5)	1 (0.5)		2 (1.0)	
Withdrawn due to Adverse Events, n (%)	0 (0.0)	1 (0.5)	0 (0.0)		0 (0.0)	
Withdrawn due to Lack of Efficacy, n (%)	Not applicable					
Withdrawn for other reasons, n (%)	0 (0.0)	0 (0.0)	1 (0.5)		2 (1.0)	
Demographics	AS50 1/4 Group	AS50 1/2 Group	Flu_Eld Group		Flu_Yng Group	
N (Total Vaccinated cohort)	198	199	200		203	
Females: Males	96:102	95:104	90:110		103:100	
Mean Age, years (SD)	72.6 (5.67)	73.0 (6.03)	72.7 (5.43)		27.4 (6.25)	
Caucasian / European heritage, n (%)	193 (97.5)	195 (98.0)	200 (100)		197 (97.0)	
Extended Safety Follow-up						
Number of subjects	AS50 1/4 Group	AS50 1/2 Group	Flu_Eld Group		Flu_Yng Group	
Planned, N	200	200	200		200	
Randomized, N (Total Vaccinated cohort)	198	199	200		203	
Completed, n (%)	196 (99.0)	193 (97.0)	198 (99.0)		189 (93.1)	
Total Number Subjects Withdrawn, n (%)	2 (1.0)	6 (3.0)	2 (1.0)		14 (6.9)	
Withdrawn due to Adverse Events, n (%)	1 (0.5)	3 (1.5)	0 (0.0)		0 (0.0)	
Withdrawn due to Lack of Efficacy, n (%)	Not applicable					
Withdrawn for other reasons, n (%)	1 (0.5)	3 (1.5)	2 (1.0)		14 (6.9)	
Primary Efficacy Results: Contour plot of the overall desirability (ATP cohort for immunogenicity HI)						



Primary Efficacy Results: Estimated ratio of GMTs of each adjuvanted influenza vaccine over Flu-2 for subjects aged 65 years and older for each vaccine strain at Day 21 (ATP cohort for immunogenicity HI)

Vaccine strain	Group	Estimated GMT ratio		
		Value	90% CI	
			LL	UL
A/Solomon Islands	AS03 1/4	1.38	1.13	1.69
	AS03 1/2	1.73	1.44	2.09
	AS03 1/1	1.62	1.33	1.99
	AS25 1/4	1.49	1.23	1.80
	AS25 1/2	1.93	1.60	2.34
	AS25 1/1	1.95	1.59	2.38
	AS50 1/4	1.36	1.12	1.65
	AS50 1/2	1.82	1.50	2.21
A/Wisconsin	AS03 1/4	1.54	1.29	1.85
	AS03 1/2	1.77	1.49	2.09
	AS03 1/1	1.91	1.59	2.29
	AS25 1/4	1.57	1.32	1.86
	AS25 1/2	1.90	1.60	2.26
	AS25 1/1	2.31	1.93	2.77
	AS50 1/4	1.43	1.20	1.70
	AS50 1/2	1.84	1.54	2.19
B/Malaysia	AS03 1/4	0.96	0.83	1.11
	AS03 1/2	1.06	0.93	1.21
	AS03 1/1	1.13	0.98	1.31
	AS25 1/4	1.02	0.89	1.17
	AS25 1/2	1.16	1.02	1.33
	AS25 1/1	1.31	1.13	1.52
	AS50 1/4	1.00	0.87	1.15
	AS50 1/2	1.17	1.01	1.34

90% CI = 90% confidence interval for the GMT ratio; LL = Lower Limit, UL = Upper Limit

Criterion for evaluation of the objective: LLs of the 90% CIs for the estimated GMT ratio > 1

Primary Efficacy Results: Seropositivity rates and GMTs for HI antibody titer at Day 0 and Day 21 (ATP cohort for immunogenicity HI)

Vaccine strain	Group	Timing	N	≥ 1:10	GMT
----------------	-------	--------	---	--------	-----

				n	%	95% CI		value	95% CI	
						LL	UL		LL	UL
A/Solomon Islands	AS03 1/4	PRE	191	97	50.8	43.5	58.1	10.6	9.3	12.2
		PI(D21)*	191	184	96.3	92.6	98.5	82.3	69.7	97.1
	AS03 1/2	PRE	191	91	47.6	40.4	55.0	10.8	9.4	12.4
		PI(D21)*	192	188	97.9	94.8	99.4	102.2	87.0	119.9
	AS03 1/1	PRE	189	86	45.5	38.3	52.9	10.1	8.8	11.5
		PI(D21)*	189	185	97.9	94.7	99.4	98.2	84.3	114.3
	AS25 1/4	PRE	194	97	50.0	42.8	57.2	10.6	9.3	12.1
		PI(D21)*	194	189	97.4	94.1	99.2	91.7	76.9	109.3
	AS25 1/2	PRE	192	97	50.5	43.2	57.8	12.0	10.3	14.0
		PI(D21)*	192	190	99.0	96.3	99.9	113.2	96.0	133.6
	AS25 1/1	PRE	193	88	45.6	38.4	52.9	9.9	8.6	11.3
		PI(D21)*	193	188	97.4	94.1	99.2	114.4	97.1	134.8
	AS50 1/4	PRE	192	87	45.3	38.1	52.6	10.2	8.9	11.7
		PI(D21)*	192	183	95.3	91.3	97.8	78.5	65.9	93.5
	AS50 1/2	PRE	189	91	48.1	40.8	55.5	10.3	9.0	11.9
		PI(D21)*	189	183	96.8	93.2	98.8	111.8	93.3	134.0
	Flu_Eld	PRE	187	88	47.1	39.7	54.5	10.7	9.2	12.4
		PI(D21)*	188	177	94.1	89.8	97.0	59.6	49.6	71.7
	Flu_Yng	PRE	197	122	61.9	54.8	68.7	21.3	17.1	26.5
		PI(D21)	197	195	99.0	96.4	99.9	271.6	224.6	328.4
A/Wisconsin	AS03 1/4	PRE	191	176	92.1	87.4	95.5	59.9	49.5	72.4
		PI(D21)*	191	190	99.5	97.1	100	276.2	238.8	319.6
	AS03 1/2	PRE	191	168	88.0	82.5	92.2	51.2	41.9	62.4
		PI(D21)*	192	192	100	98.1	100	350.2	298.0	411.4
	AS03 1/1	PRE	189	168	88.9	83.5	93.0	44.4	36.5	54.0
		PI(D21)*	189	189	100	98.1	100	351.3	304.8	404.8
	AS25 1/4	PRE	194	175	90.2	85.1	94.0	65.7	53.7	80.4
		PI(D21)*	194	194	100	98.1	100	309.2	264.9	361.0
	AS25 1/2	PRE	192	174	90.6	85.6	94.3	61.1	50.6	73.8
		PI(D21)*	192	192	100	98.1	100	331.1	289.6	378.6
	AS25 1/1	PRE	193	173	89.6	84.4	93.6	55.8	46.2	67.4
		PI(D21)*	193	192	99.5	97.1	100	438.1	379.7	505.4
	AS50 1/4	PRE	192	168	87.5	82.0	91.8	54.6	44.5	67.0
		PI(D21)*	192	191	99.5	97.1	100	263.3	225.3	307.7
	AS50 1/2	PRE	189	166	87.8	82.3	92.1	57.8	47.1	70.9
		PI(D21)*	189	188	99.5	97.1	100	347.5	296.4	407.3
	Flu_Eld	PRE	187	169	90.4	85.2	94.2	61.0	49.8	74.7
		PI(D21)*	188	188	100	98.1	100	186.7	158.0	220.7
	Flu_Yng	PRE	197	166	84.3	78.4	89.1	47.8	39.2	58.4
		PI(D21)	197	197	100	98.1	100	380.2	331.6	435.9
B/Malaysia	AS03 1/4	PRE	191	178	93.2	88.6	96.3	58.6	49.8	68.9
		PI(D21)*	191	190	99.5	97.1	100	147.1	129.1	167.6
	AS03 1/2	PRE	191	180	94.2	89.9	97.1	53.7	45.7	63.2
		PI(D21)*	192	192	100	98.1	100	163.1	142.5	186.6
	AS03 1/1	PRE	189	177	93.7	89.2	96.7	57.0	48.2	67.5
		PI(D21)*	189	189	100	98.1	100	172.1	149.9	197.6
	AS25 1/4	PRE	194	183	94.3	90.1	97.1	62.6	53.3	73.4
		PI(D21)*	194	194	100	98.1	100	152.4	134.4	172.7
	AS25 1/2	PRE	192	184	95.8	92.0	98.2	77.8	66.0	91.7
		PI(D21)*	192	192	100	98.1	100	181.4	158.9	207.1
	AS25 1/1	PRE	193	186	96.4	92.7	98.5	62.9	53.9	73.4
		PI(D21)*	193	193	100	98.1	100	202.0	179.7	227.1

	AS50 1/4	PRE	192	179	93.2	88.7	96.3	58.2	49.0	69.1
		PI(D21)*	192	192	100	98.1	100	155.7	134.8	179.8
	AS50 1/2	PRE	189	176	93.1	88.5	96.3	62.6	53.0	74.0
		PI(D21)*	189	189	100	98.1	100	174.6	152.0	200.7
	Flu_Eld	PRE	187	179	95.7	91.7	98.1	66.5	56.5	78.3
		PI(D21)*	188	188	100	98.1	100	153.0	135.2	173.1
	Flu_Yng	PRE	197	135	68.5	61.5	74.9	23.4	19.1	28.7
		PI(D21)	197	197	100	98.1	100	281.9	241.7	328.7

GMT = geometric mean antibody titer calculated on all subjects
N = number of subjects with available results
n/% = number/percentage of subjects with titer within the specified range
95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit
PRE = Pre-vaccination dose 1 (Day 0)
PI(D21) = Post-vaccination dose 1 (Day 21)

Secondary Outcome Variable(s): Seropositivity rates and GMTs for HI antibody titer at Day 180 (ATP cohort for persistence for HI)

Vaccine strain	Group	N	≥ 1:10				GMT		
			n	%	95% CI		value	95% CI	
					LL	UL		LL	UL
A/Solomon Islands	AS03 1/4	186	157	84.4	78.4	89.3	30.6	25.8	36.3
	AS03 1/2	186	164	88.2	82.6	92.4	35.1	29.7	41.5
	AS03 1/1	180	161	89.4	84.0	93.5	36.3	30.7	42.8
	AS25 1/4	184	163	88.6	83.1	92.8	32.5	27.6	38.2
	AS25 1/2	180	163	90.6	85.3	94.4	40.4	34.1	47.9
	AS25 1/1	187	163	87.2	81.5	91.6	33.7	28.6	39.7
	AS50 1/4	187	159	85.0	79.1	89.8	29.9	25.5	35.0
	AS50 1/2	174	160	92.0	86.9	95.5	39.8	33.6	47.2
	Flu_Eld	181	147	81.2	74.8	86.6	23.7	20.3	27.7
	Flu_Yng	165	154	93.3	88.4	96.6	114.7	91.8	143.5
A/Wisconsin	AS03 1/4	186	186	100	98.0	100	131.5	112.6	153.5
	AS03 1/2	186	183	98.4	95.4	99.7	139.8	118.1	165.5
	AS03 1/1	180	178	98.9	96.0	99.9	133.4	112.7	158.1
	AS25 1/4	184	179	97.3	93.8	99.1	134.0	113.1	158.7
	AS25 1/2	180	179	99.4	96.9	100	144.7	124.9	167.5
	AS25 1/1	187	186	99.5	97.1	100	181.4	156.5	210.3
	AS50 1/4	187	182	97.3	93.9	99.1	118.2	99.8	140.0
	AS50 1/2	174	170	97.7	94.2	99.4	145.3	121.9	173.2
	Flu_Eld	181	177	97.8	94.4	99.4	92.5	78.7	108.6
	Flu_Yng	165	164	99.4	96.7	100	193.2	163.5	228.3
B/Malaysia	AS03 1/4	186	186	100	98.0	100	92.7	81.2	106.0
	AS03 1/2	186	186	100	98.0	100	94.3	81.6	109.1
	AS03 1/1	180	178	98.9	96.0	99.9	100.9	87.7	116.1
	AS25 1/4	184	180	97.8	94.5	99.4	87.4	75.9	100.6
	AS25 1/2	180	180	100	98.0	100	109.2	94.9	125.6
	AS25 1/1	187	184	98.4	95.4	99.7	111.4	97.2	127.6
	AS50 1/4	187	183	97.9	94.6	99.4	89.0	76.1	104.0
	AS50 1/2	174	173	99.4	96.8	100	97.7	84.7	112.7
	Flu_Eld	181	181	100	98.0	100	96.6	83.8	111.3
	Flu_Yng	165	163	98.8	95.7	99.9	132.4	110.2	159.0

GMT = geometric mean antibody titer
N = number of subjects with available results
n/%=number/percentage of seropositive subjects (HI titer ≥ 1:10)
95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Secondary Outcome Variable(s): SCR for HI antibody titer at Day 21 (ATP cohort for immunogenicity HI)

Vaccine strain	Group	N	SCR
----------------	-------	---	-----

			n	%	95% CI	
					LL	UL
A/Solomon Islands	AS03 1/4	191	133	69.6	62.6	76.1
	AS03 1/2	191	138	72.3	65.3	78.5
	AS03 1/1	189	154	81.5	75.2	86.7
	AS25 1/4	194	130	67.0	59.9	73.6
	AS25 1/2	192	142	74.0	67.1	80.0
	AS25 1/1	193	151	78.2	71.7	83.8
	AS50 1/4	192	129	67.2	60.1	73.8
	AS50 1/2	189	146	77.2	70.6	83.0
	Flu_Eld	187	99	52.9	45.5	60.3
	Flu_Yng	197	135	68.5	61.5	74.9
A/Wisconsin	AS03 1/4	191	108	56.5	49.2	63.7
	AS03 1/2	191	124	64.9	57.7	71.7
	AS03 1/1	189	141	74.6	67.8	80.6
	AS25 1/4	194	104	53.6	46.3	60.8
	AS25 1/2	192	124	64.6	57.4	71.3
	AS25 1/1	193	142	73.6	66.8	79.6
	AS50 1/4	192	110	57.3	50.0	64.4
	AS50 1/2	189	131	69.3	62.2	75.8
	Flu_Eld	187	69	36.9	30.0	44.2
	Flu_Yng	197	130	66.0	58.9	72.6
B/Malaysia	AS03 1/4	191	47	24.6	18.7	31.3
	AS03 1/2	191	73	38.2	31.3	45.5
	AS03 1/1	189	65	34.4	27.6	41.6
	AS25 1/4	194	44	22.7	17.0	29.2
	AS25 1/2	192	45	23.4	17.6	30.1
	AS25 1/1	193	79	40.9	33.9	48.2
	AS50 1/4	192	50	26.0	20.0	32.9
	AS50 1/2	189	55	29.1	22.7	36.1
	Flu_Eld	187	47	25.1	19.1	32.0
	Flu_Yng	197	147	74.6	67.9	80.5
Seroconversion defined as: For initially seronegative subjects, antibody titer $\geq 1:40$ after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer N = Number of subjects with pre- and post-vaccination results available n/%=number/percentage of seroconverted subjects 95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit						
Secondary Outcome Variable(s): SCR for HI antibody titer at Day 180 (ATP cohort for persistence for HI)						
Vaccine strain	Group	N	SCR			
			n	%	95% CI	
					LL	UL
A/Solomon Islands	AS03 1/4	186	64	34.4	27.6	41.7
	AS03 1/2	186	73	39.2	32.2	46.7
	AS03 1/1	180	74	41.1	33.8	48.7
	AS25 1/4	184	68	37.0	30.0	44.4
	AS25 1/2	180	60	33.3	26.5	40.7
	AS25 1/1	187	77	41.2	34.0	48.6
	AS50 1/4	187	60	32.1	25.5	39.3
	AS50 1/2	174	67	38.5	31.2	46.2
	Flu_Eld	180	42	23.3	17.4	30.2
	Flu_Yng	165	90	54.5	46.6	62.3
A/Wisconsin	AS03 1/4	186	47	25.3	19.2	32.1
	AS03 1/2	186	59	31.7	25.1	38.9
	AS03 1/1	180	61	33.9	27.0	41.3

	AS25 1/4	184	46	25.0	18.9	31.9
	AS25 1/2	180	50	27.8	21.4	34.9
	AS25 1/1	187	74	39.6	32.5	47.0
	AS50 1/4	187	37	19.8	14.3	26.2
	AS50 1/2	174	49	28.2	21.6	35.5
	Flu_Eld	180	23	12.8	8.3	18.6
	Flu_Yng	165	74	44.8	37.1	52.8
B/Malaysia	AS03 1/4	186	23	12.4	8.0	18.0
	AS03 1/2	186	23	12.4	8.0	18.0
	AS03 1/1	180	25	13.9	9.2	19.8
	AS25 1/4	184	19	10.3	6.3	15.7
	AS25 1/2	180	16	8.9	5.2	14.0
	AS25 1/1	187	32	17.1	12.0	23.3
	AS50 1/4	187	19	10.2	6.2	15.4
	AS50 1/2	174	20	11.5	7.2	17.2
	Flu_Eld	180	17	9.4	5.6	14.7
	Flu_Yng	165	90	54.5	46.6	62.3

Seroconversion defined as:

For initially seronegative subjects, antibody titer $\geq 1:40$ after vaccination

For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer

N = Number of subjects with pre- and post-vaccination results available

n/% = Number/percentage of seroconverted subjects

95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Secondary Outcome Variable(s): SCF for HI antibody titer at Day 21 (ATP cohort for immunogenicity HI)

Vaccine strain	Group	N	SCF		
			Value	95% CI	
				LL	UL
A/Solomon Islands	AS03 1/4	191	7.7	6.5	9.2
	AS03 1/2	191	9.4	7.8	11.3
	AS03 1/1	189	9.8	8.3	11.5
	AS25 1/4	194	8.6	7.2	10.4
	AS25 1/2	192	9.4	8.0	11.1
	AS25 1/1	193	11.6	9.7	13.9
	AS50 1/4	192	7.7	6.5	9.2
	AS50 1/2	189	10.8	9.0	13.0
	Flu_Eld	187	5.6	4.7	6.8
	Flu_Yng	197	12.8	10.0	16.3
A/Wisconsin	AS03 1/4	191	4.6	3.9	5.4
	AS03 1/2	191	6.8	5.6	8.1
	AS03 1/1	189	7.9	6.6	9.5
	AS25 1/4	194	4.7	4.0	5.5
	AS25 1/2	192	5.4	4.6	6.3
	AS25 1/1	193	7.8	6.5	9.5
	AS50 1/4	192	4.8	4.1	5.7
	AS50 1/2	189	6.0	5.1	7.1
	Flu_Eld	187	3.1	2.6	3.6
	Flu_Yng	197	7.9	6.4	9.8
B/Malaysia	AS03 1/4	191	2.5	2.2	2.8
	AS03 1/2	191	3.0	2.6	3.5
	AS03 1/1	189	3.0	2.6	3.5
	AS25 1/4	194	2.4	2.2	2.8
	AS25 1/2	192	2.3	2.1	2.6
	AS25 1/1	193	3.2	2.8	3.7
	AS50 1/4	192	2.7	2.3	3.1
	AS50 1/2	189	2.8	2.4	3.2

	Flu_Eld	187	2.3	2.0	2.6
	Flu_Yng	197	12.0	9.7	15.0
N = Number of subjects with pre- and post-vaccination results available					
SCF = Seroconversion Factor or geometric mean ratio (mean[log10(POST/PRE)])					
95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit					
Secondary Outcome Variable(s): SCF for HI antibody titer at Day 180 (ATP cohort for persistence for HI)					
Vaccine strain	Group	N	SCF		
			Value	95% CI	
				LL	UL
A/Solomon Islands	AS03 1/4	186	2.9	2.5	3.4
	AS03 1/2	186	3.3	2.8	3.9
	AS03 1/1	180	3.5	3.1	4.1
	AS25 1/4	184	3.0	2.6	3.5
	AS25 1/2	180	3.3	2.9	3.8
	AS25 1/1	187	3.5	2.9	4.1
	AS50 1/4	187	2.9	2.5	3.3
	AS50 1/2	174	3.8	3.2	4.4
	Flu_Eld	180	2.2	1.9	2.6
	Flu_Yng	165	5.7	4.5	7.2
A/Wisconsin	AS03 1/4	186	2.2	1.9	2.6
	AS03 1/2	186	2.7	2.3	3.1
	AS03 1/1	180	2.9	2.5	3.3
	AS25 1/4	184	2.0	1.8	2.3
	AS25 1/2	180	2.4	2.1	2.7
	AS25 1/1	187	3.1	2.7	3.6
	AS50 1/4	187	2.1	1.8	2.4
	AS50 1/2	174	2.5	2.2	2.9
	Flu_Eld	180	1.6	1.4	1.8
	Flu_Yng	165	4.0	3.2	5.0
B/Malaysia	AS03 1/4	186	1.7	1.5	1.9
	AS03 1/2	186	1.7	1.5	1.9
	AS03 1/1	180	1.7	1.5	1.9
	AS25 1/4	184	1.4	1.3	1.6
	AS25 1/2	180	1.4	1.3	1.6
	AS25 1/1	187	1.8	1.6	2.0
	AS50 1/4	187	1.5	1.4	1.7
	AS50 1/2	174	1.6	1.4	1.8
	Flu_Eld	180	1.5	1.3	1.7
	Flu_Yng	165	5.6	4.5	7.0

N = Number of subjects with pre- and post-vaccination results available							
SCF = Seroconversion Factor or geometric mean ratio (mean[log10(POST/PRE)])							
95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit							
Secondary Outcome Variable(s): SPR for HI antibody titer at Day 0 and 21 (ATP cohort for immunogenicity HI)							
Vaccine strain	Group	Timing	N	SPR			
				n	%	95% CI	
						LL	UL
A/Solomon Islands	AS03 1/4	PRE	191	27	14.1	9.5	19.9
		PI(D21)	191	160	83.8	77.8	88.7
	AS03 1/2	PRE	191	31	16.2	11.3	22.2
		PI(D21)	192	168	87.5	82.0	91.8
	AS03 1/1	PRE	189	25	13.2	8.7	18.9
		PI(D21)	189	171	90.5	85.4	94.3
	AS25 1/4	PRE	194	33	17.0	12.0	23.1

[illegible]

n/%=number/percentage of seroprotected subjects (HI titer \geq 1:40)
95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit
PRE = pre-vaccination dose 1 (Day 0)
PI(D21) = post-vaccination dose 1 (Day 21)

Secondary Outcome Variable(s): SPR for HI antibody titer at Day 180 (ATP cohort for persistence for HI)

Vaccine strain	Group	N	SPR			
			n	%	95% CI	
					LL	UL
A/Solomon Islands	AS03 1/4	186	94	50.5	43.1	57.9
	AS03 1/2	186	111	59.7	52.3	66.8
	AS03 1/1	180	105	58.3	50.8	65.6
	AS25 1/4	184	105	57.1	49.6	64.3
	AS25 1/2	180	103	57.2	49.6	64.6
	AS25 1/1	187	104	55.6	48.2	62.9
	AS50 1/4	187	100	53.5	46.1	60.8
	AS50 1/2	174	100	57.5	49.8	64.9
	Flu_Eld	181	77	42.5	35.2	50.1
	Flu_Yng	165	135	81.8	75.1	87.4
A/Wisconsin	AS03 1/4	186	172	92.5	87.7	95.8
	AS03 1/2	186	170	91.4	86.4	95.0
	AS03 1/1	180	162	90.0	84.7	94.0
	AS25 1/4	184	164	89.1	83.7	93.2
	AS25 1/2	180	170	94.4	90.0	97.3
	AS25 1/1	187	179	95.7	91.7	98.1
	AS50 1/4	187	166	88.8	83.3	92.9
	AS50 1/2	174	160	92.0	86.9	95.5
	Flu_Eld	181	156	86.2	80.3	90.9
	Flu_Yng	165	158	95.8	91.5	98.3
B/Malaysia	AS03 1/4	186	167	89.8	84.5	93.7
	AS03 1/2	186	166	89.2	83.9	93.3
	AS03 1/1	180	168	93.3	88.6	96.5
	AS25 1/4	184	168	91.3	86.3	94.9
	AS25 1/2	180	166	92.2	87.3	95.7
	AS25 1/1	187	176	94.1	89.7	97.0
	AS50 1/4	187	158	84.5	78.5	89.4
	AS50 1/2	174	162	93.1	88.3	96.4
	Flu_Eld	181	162	89.5	84.1	93.6
	Flu_Yng	165	144	87.3	81.2	91.9

N = Number of subjects with available results
n/% = number/percentage of seroprotected subjects (HI titer \geq 1:40)
95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Secondary Outcome Variable(s): Descriptive Statistics on the frequency cytokine-positive CD4 T-cells (per million CD4 T-cells) for each strain at Days 0 and 21 (ATP cohort for immunogenicity CMI)

Test description	Vaccine strain	Group	Timing	N	GM	SD	Median
CD4-All doubles	A/Solomon Islands	AS03 1/4	PRE	23	177.48	278.18	356.00
			PI(D21)	24	441.16	517.73	499.50
		AS03 1/2	PRE	18	283.18	319.74	294.00
			PI(D21)	19	856.00	685.35	1030.00
		AS03 1/1	PRE	24	204.49	236.05	338.00
			PI(D21)	25	704.14	778.07	775.00
		AS25 1/4	PRE	24	200.21	480.41	257.00
			PI(D21)	24	494.63	883.53	729.50
		AS25 1/2	PRE	23	193.35	324.34	245.00
			PI(D21)	24	483.24	481.37	737.00
		AS25 1/1	PRE	23	177.44	297.52	281.00
			PI(D21)	23	808.90	858.38	1004.00

		AS50 1/4	PRE	22	199.80	310.58	265.00
			PI(D21)	23	655.32	616.75	643.00
		AS50 1/2	PRE	20	222.58	282.91	359.50
			PI(D21)	23	797.68	5271.86	1165.00
		Flu_Eld	PRE	22	156.21	518.89	295.50
			PI(D21)	23	536.24	578.48	594.00
		Flu_Yng	PRE	18	538.72	442.78	753.50
			PI(D21)	23	1027.23	838.01	1166.00
	A/Wisconsin	AS03 1/4	PRE	23	583.77	563.98	652.00
			PI(D21)	24	1016.63	990.97	1148.50
		AS03 1/2	PRE	18	488.70	540.66	787.50
			PI(D21)	19	1491.86	899.50	1617.00
		AS03 1/1	PRE	24	584.25	626.26	745.50
			PI(D21)	25	1140.56	955.61	1515.00
		AS25 1/4	PRE	24	309.67	517.11	468.50
			PI(D21)	24	1015.18	1044.87	914.00
		AS25 1/2	PRE	23	538.87	691.59	639.00
			PI(D21)	24	1051.06	1024.97	888.00
		AS25 1/1	PRE	23	702.79	3741.48	706.00
			PI(D21)	23	1998.33	2730.32	1762.00
		AS50 1/4	PRE	22	457.98	321.69	473.50
			PI(D21)	23	1234.37	830.47	1277.00
		AS50 1/2	PRE	20	594.26	598.83	592.50
			PI(D21)	23	1302.34	3490.03	1122.00
		Flu_Eld	PRE	22	427.71	745.78	558.00
			PI(D21)	23	922.62	1170.30	887.00
		Flu_Yng	PRE	18	821.78	646.48	903.00
			PI(D21)	23	1455.68	870.69	1427.00
	B/Malaysia	AS03 1/4	PRE	23	407.18	456.82	625.00
			PI(D21)	24	1025.01	736.55	1090.50
		AS03 1/2	PRE	18	596.53	400.24	836.00
			PI(D21)	19	1614.14	953.74	1363.00
		AS03 1/1	PRE	24	500.81	734.64	540.50
			PI(D21)	25	1005.72	1314.69	1588.00
		AS25 1/4	PRE	24	250.48	375.23	460.50
			PI(D21)	24	817.57	675.70	824.50
		AS25 1/2	PRE	23	490.56	546.12	489.00
			PI(D21)	24	1019.48	698.91	1061.00
		AS25 1/1	PRE	23	259.15	278.35	441.00
			PI(D21)	23	1255.53	941.27	1362.00
		AS50 1/4	PRE	22	403.06	482.16	378.50
			PI(D21)	23	1153.76	699.26	1048.00
		AS50 1/2	PRE	20	442.39	315.27	446.00
			PI(D21)	23	1057.60	4968.52	1477.00
		Flu_Eld	PRE	22	301.23	584.68	492.00
			PI(D21)	23	781.66	880.46	829.00
		Flu_Yng	PRE	18	1098.75	909.18	1027.00
			PI(D21)	23	1707.62	1591.31	1605.00
CD4-CD40L	A/Solomon Islands	AS03 1/4	PRE	23	187.19	277.14	356.00
			PI(D21)	24	418.24	523.39	489.50
		AS03 1/2	PRE	18	285.19	319.80	278.50
			PI(D21)	19	657.41	684.48	1105.00
		AS03 1/1	PRE	24	193.56	236.01	339.50
			PI(D21)	25	641.98	752.95	723.00

		AS25 1/4	PRE	24	141.26	500.24	231.00
			PI(D21)	24	471.56	881.73	619.00
		AS25 1/2	PRE	23	192.02	314.38	274.00
			PI(D21)	24	391.29	474.16	703.50
		AS25 1/1	PRE	23	167.87	296.47	277.00
			PI(D21)	23	510.16	871.38	806.00
		AS50 1/4	PRE	22	153.91	311.96	255.50
			PI(D21)	23	599.32	592.08	630.00
		AS50 1/2	PRE	20	165.48	281.57	316.50
			PI(D21)	23	697.39	5282.26	1065.00
		Flu_Eld	PRE	22	150.60	512.37	290.00
			PI(D21)	23	406.14	571.70	627.00
		Flu_Yng	PRE	18	504.55	441.35	743.00
			PI(D21)	23	967.83	848.55	1129.00
	A/Wisconsin	AS03 1/4	PRE	23	555.20	555.43	602.00
			PI(D21)	24	941.04	994.45	1152.50
		AS03 1/2	PRE	18	477.12	531.36	877.00
			PI(D21)	19	1438.93	881.80	1597.00
		AS03 1/1	PRE	24	527.80	613.23	753.50
			PI(D21)	25	1014.97	933.09	1453.00
		AS25 1/4	PRE	24	284.63	522.58	400.50
			PI(D21)	24	940.53	1065.84	879.50
		AS25 1/2	PRE	23	511.21	679.89	524.00
			PI(D21)	24	977.44	970.75	884.50
		AS25 1/1	PRE	23	587.17	1872.24	712.00
			PI(D21)	23	1763.75	1858.49	1713.00
		AS50 1/4	PRE	22	418.98	333.83	472.50
			PI(D21)	23	1162.09	715.63	1277.00
		AS50 1/2	PRE	20	568.96	559.46	600.50
			PI(D21)	23	1156.07	3501.25	1146.00
	B/Malaysia	Flu_Eld	PRE	22	322.37	713.98	518.50
			PI(D21)	23	798.75	1155.23	841.00
		Flu_Yng	PRE	18	742.80	659.21	856.50
			PI(D21)	23	1383.25	871.98	1393.00
		AS03 1/4	PRE	23	387.03	429.86	594.00
			PI(D21)	24	926.13	749.19	1071.50
		AS03 1/2	PRE	18	587.72	396.47	833.50
			PI(D21)	19	1570.30	962.36	1346.00
		AS03 1/1	PRE	24	446.80	736.88	540.00
			PI(D21)	25	958.63	1315.41	1528.00
		AS25 1/4	PRE	24	219.83	386.13	425.50
			PI(D21)	24	754.45	694.91	746.50
		AS25 1/2	PRE	23	479.21	550.01	492.00
			PI(D21)	24	975.92	710.25	1009.00
		AS25 1/1	PRE	23	256.73	280.28	464.00
			PI(D21)	23	1160.31	959.34	1298.00
		AS50 1/4	PRE	22	383.93	466.87	371.00
			PI(D21)	23	1039.13	699.33	1048.00
		AS50 1/2	PRE	20	431.32	319.06	462.50
			PI(D21)	23	957.22	5023.06	1304.00
		Flu_Eld	PRE	22	342.65	589.08	489.00
			PI(D21)	23	707.72	874.64	813.00
		Flu_Yng	PRE	18	1076.46	903.85	1038.00
			PI(D21)	23	1614.08	1617.78	1568.00

CD4-IFN γ	A/Solomon Islands	AS03 1/4	PRE	23	202.65	195.65	336.00
			PI(D21)	24	398.57	370.41	467.50
		AS03 1/2	PRE	18	190.19	245.89	214.00
			PI(D21)	19	636.42	570.57	715.00
		AS03 1/1	PRE	24	158.04	192.23	256.50
			PI(D21)	25	532.84	488.63	609.00
		AS25 1/4	PRE	24	235.01	355.44	289.50
			PI(D21)	24	426.15	660.07	490.50
		AS25 1/2	PRE	23	171.07	194.84	151.00
			PI(D21)	24	379.49	361.80	400.00
		AS25 1/1	PRE	23	137.02	189.76	250.00
			PI(D21)	23	543.09	681.65	726.00
		AS50 1/4	PRE	22	203.95	254.48	204.50
			PI(D21)	23	467.66	450.93	453.00
		AS50 1/2	PRE	20	184.52	211.26	247.00
			PI(D21)	23	576.14	4664.15	737.00
		Flu_Eld	PRE	22	198.86	422.78	213.00
			PI(D21)	23	442.66	449.36	397.00
		Flu_Yng	PRE	18	380.34	384.07	477.50
			PI(D21)	23	755.12	645.89	854.00
	A/Wisconsin	AS03 1/4	PRE	23	361.99	378.72	398.00
			PI(D21)	24	644.07	707.63	673.50
		AS03 1/2	PRE	18	350.04	325.28	311.50
			PI(D21)	19	891.98	719.87	1094.00
		AS03 1/1	PRE	24	332.39	326.71	354.50
			PI(D21)	25	809.46	590.21	965.00
		AS25 1/4	PRE	24	295.56	424.20	324.50
			PI(D21)	24	606.43	745.80	632.50
		AS25 1/2	PRE	23	243.93	321.57	330.00
			PI(D21)	24	651.21	651.51	664.50
		AS25 1/1	PRE	23	495.18	3550.69	383.00
			PI(D21)	23	1293.10	2390.91	1151.00
		AS50 1/4	PRE	22	305.13	248.40	358.00
			PI(D21)	23	718.87	619.16	896.00
		AS50 1/2	PRE	20	310.45	276.10	353.00
			PI(D21)	23	691.57	2944.57	726.00
		Flu_Eld	PRE	22	272.34	453.35	322.00
			PI(D21)	23	548.91	732.46	574.00
		Flu_Yng	PRE	18	589.57	493.89	592.00
			PI(D21)	23	976.96	643.43	1043.00
	B/Malaysia	AS03 1/4	PRE	23	336.70	352.20	349.00
			PI(D21)	24	716.86	601.16	784.50
		AS03 1/2	PRE	18	403.08	319.99	512.50
			PI(D21)	19	1163.80	865.47	1174.00
		AS03 1/1	PRE	24	322.07	631.98	340.50
			PI(D21)	25	855.95	1073.89	901.00
		AS25 1/4	PRE	24	302.23	249.59	333.50
			PI(D21)	24	509.84	520.06	491.50
		AS25 1/2	PRE	23	248.66	236.24	305.00
			PI(D21)	24	611.65	527.80	551.50
		AS25 1/1	PRE	23	237.57	200.43	295.00
			PI(D21)	23	852.80	715.28	791.00
		AS50 1/4	PRE	22	277.94	372.05	241.50
			PI(D21)	23	745.46	575.21	695.00

CD4-IL2		AS50 1/2	PRE	20	210.23	266.19	324.50
			PI(D21)	23	709.84	4385.83	964.00
		Flu_Eld	PRE	22	256.03	440.55	313.00
			PI(D21)	23	523.15	697.47	528.00
		Flu_Yng	PRE	18	874.82	729.66	829.00
			PI(D21)	23	1306.18	1346.37	1138.00
		AS03 1/4	PRE	23	181.54	242.60	263.00
			PI(D21)	24	299.14	421.84	421.00
	A/Solomon Islands	AS03 1/2	PRE	18	193.42	297.22	233.50
			PI(D21)	19	664.46	582.79	751.00
		AS03 1/1	PRE	24	188.29	215.39	317.00
			PI(D21)	25	559.98	642.32	606.00
		AS25 1/4	PRE	24	150.59	407.63	233.50
			PI(D21)	24	415.13	691.39	504.00
		AS25 1/2	PRE	23	152.22	284.11	201.00
			PI(D21)	24	409.73	365.35	603.00
		AS25 1/1	PRE	23	157.54	255.06	227.00
			PI(D21)	23	677.81	689.59	997.00
		AS50 1/4	PRE	22	161.81	293.16	228.00
			PI(D21)	23	529.19	520.65	509.00
		AS50 1/2	PRE	20	170.79	253.02	288.50
			PI(D21)	23	678.22	4760.15	900.00
		Flu_Eld	PRE	22	122.12	451.59	279.00
			PI(D21)	23	461.05	498.00	428.00
		Flu_Yng	PRE	18	356.84	313.43	495.00
			PI(D21)	23	813.73	693.31	945.00
	A/Wisconsin	AS03 1/4	PRE	23	406.48	508.99	406.00
			PI(D21)	24	747.93	778.49	812.50
		AS03 1/2	PRE	18	382.61	428.51	580.00
			PI(D21)	19	1082.78	712.53	1129.00
		AS03 1/1	PRE	24	516.80	421.85	664.00
			PI(D21)	25	1010.24	772.39	1254.00
		AS25 1/4	PRE	24	251.35	445.04	355.50
			PI(D21)	24	762.07	766.05	737.50
		AS25 1/2	PRE	23	388.89	560.47	412.00
			PI(D21)	24	792.75	828.41	709.00
		AS25 1/1	PRE	23	532.86	708.29	626.00
			PI(D21)	23	1425.03	1236.35	1513.00
		AS50 1/4	PRE	22	393.79	295.93	406.50
			PI(D21)	23	908.72	680.48	997.00
		AS50 1/2	PRE	20	470.64	443.13	549.00
			PI(D21)	23	1041.76	2883.12	937.00
		Flu_Eld	PRE	22	343.41	607.93	415.50
			PI(D21)	23	733.36	900.95	735.00
		Flu_Yng	PRE	18	589.89	469.14	742.00
			PI(D21)	23	1061.62	635.42	1146.00
	B/Malaysia	AS03 1/4	PRE	23	277.98	394.46	494.00
			PI(D21)	24	791.31	616.06	913.00
		AS03 1/2	PRE	18	491.65	369.85	724.00
			PI(D21)	19	1295.22	856.91	1087.00
		AS03 1/1	PRE	24	434.78	621.10	463.50
			PI(D21)	25	992.50	1134.21	1273.00
		AS25 1/4	PRE	24	190.27	322.46	393.00
			PI(D21)	24	692.82	570.55	661.50

		AS25 1/2	PRE	23	411.11	457.99	432.00
			PI(D21)	24	876.95	569.97	868.00
		AS25 1/1	PRE	23	269.03	243.51	379.00
			PI(D21)	23	1038.01	765.73	935.00
		AS50 1/4	PRE	22	360.78	420.71	384.50
			PI(D21)	23	949.33	588.11	876.00
		AS50 1/2	PRE	20	333.95	309.81	360.00
			PI(D21)	23	872.00	4655.93	1229.00
		Flu_Eld	PRE	22	221.19	537.35	417.00
			PI(D21)	23	695.83	757.57	713.00
		Flu_Yng	PRE	18	871.60	724.64	759.50
			PI(D21)	23	1348.21	1359.92	1233.00
CD4-TNF α	A/Solomon Islands	AS03 1/4	PRE	23	91.32	201.60	146.00
			PI(D21)	24	234.99	298.31	312.50
		AS03 1/2	PRE	18	155.22	184.44	161.50
			PI(D21)	19	440.26	451.77	552.00
		AS03 1/1	PRE	24	130.19	152.33	191.00
			PI(D21)	25	333.95	487.76	366.00
		AS25 1/4	PRE	24	124.70	306.20	182.50
			PI(D21)	24	279.64	553.81	350.50
		AS25 1/2	PRE	23	143.44	199.20	149.00
			PI(D21)	24	296.79	289.33	364.50
		AS25 1/1	PRE	23	112.41	169.39	165.00
			PI(D21)	23	336.45	541.95	598.00
		AS50 1/4	PRE	22	100.38	185.42	116.50
			PI(D21)	23	325.65	410.44	373.00
		AS50 1/2	PRE	20	111.07	179.39	195.50
			PI(D21)	23	449.86	3979.03	542.00
		Flu_Eld	PRE	22	104.10	311.25	212.50
			PI(D21)	23	273.66	355.95	309.00
		Flu_Yng	PRE	18	234.98	234.23	373.00
			PI(D21)	23	490.23	532.90	628.00
	A/Wisconsin	AS03 1/4	PRE	23	351.26	450.82	442.00
			PI(D21)	24	712.96	700.26	751.50
		AS03 1/2	PRE	18	458.02	373.43	681.00
			PI(D21)	19	944.29	589.91	1011.00
		AS03 1/1	PRE	24	432.24	487.63	510.00
			PI(D21)	25	852.44	637.30	978.00
		AS25 1/4	PRE	24	342.30	455.39	403.00
			PI(D21)	24	623.21	728.42	565.00
		AS25 1/2	PRE	23	404.64	410.30	456.00
			PI(D21)	24	702.41	635.67	682.00
		AS25 1/1	PRE	23	600.83	3581.08	467.00
			PI(D21)	23	1293.59	2431.45	951.00
		AS50 1/4	PRE	22	303.13	263.25	334.50
			PI(D21)	23	802.15	591.12	850.00
		AS50 1/2	PRE	20	420.75	422.38	464.50
			PI(D21)	23	884.71	2654.95	865.00
		Flu_Eld	PRE	22	327.09	552.26	418.50
			PI(D21)	23	575.97	723.76	573.00
		Flu_Yng	PRE	18	667.60	450.65	802.50
			PI(D21)	23	995.86	630.33	1102.00
	B/Malaysia	AS03 1/4	PRE	23	203.89	281.14	302.00
			PI(D21)	24	509.26	451.20	494.00

		AS03 1/2	PRE	18	239.73	260.28	328.00
			PI(D21)	19	806.86	561.77	739.00
		AS03 1/1	PRE	24	225.66	501.91	319.00
			PI(D21)	25	601.64	763.90	769.00
		AS25 1/4	PRE	24	118.04	257.63	160.50
			PI(D21)	24	312.72	391.89	321.00
		AS25 1/2	PRE	23	241.23	332.43	260.00
			PI(D21)	24	518.35	419.60	516.50
		AS25 1/1	PRE	23	117.51	175.00	197.00
			PI(D21)	23	580.98	579.68	710.00
		AS50 1/4	PRE	22	152.19	297.33	238.50
			PI(D21)	23	547.64	464.44	498.00
		AS50 1/2	PRE	20	193.88	141.46	236.00
			PI(D21)	23	540.54	3022.19	825.00
		Flu_Eld	PRE	22	126.64	402.92	222.00
			PI(D21)	23	285.50	526.85	420.00
		Flu_Yng	PRE	18	605.04	641.27	523.00
			PI(D21)	23	805.41	1133.76	737.00

All doubles: T-cells producing at least 2 cytokines

N = number of subjects with available results

GM = geometric Mean

SD = Standard Deviation

PRE = pre-vaccination dose 1 (Day 0)

PI(D21) = post-vaccination dose 1 (Day 21)

Secondary Outcome Variable(s): Descriptive Statistics on the frequency cytokine-positive CD4 T-cells (per million CD4 T-cells) for each strain at Day 180 (ATP cohort for persistence for CMI)

Test description	Vaccine strain	Group	N	GM	SD	Median
CD4-ALL DOUBLES	A/Solomon Islands	AS03 1/4	21	393.50	359.42	564.00
		AS03 1/2	18	348.12	422.44	551.00
		AS03 1/1	20	666.01	663.86	676.00
		AS25 1/4	17	394.45	508.40	450.00
		AS25 1/2	21	432.70	374.70	688.00
		AS25 1/1	21	421.08	613.81	743.00
		AS50 1/4	19	357.66	470.53	463.00
		AS50 1/2	16	224.47	332.47	367.50
		Flu_Eld	16	714.85	658.37	537.50
		Flu_Yng	19	1070.14	874.71	1280.00
	A/Wisconsin	AS03 1/4	21	802.04	391.96	885.00
		AS03 1/2	18	603.15	559.07	847.50
		AS03 1/1	20	720.91	829.77	945.50
		AS25 1/4	17	463.85	832.67	448.00
		AS25 1/2	21	728.09	640.63	710.00
		AS25 1/1	21	676.69	785.39	1100.00
		AS50 1/4	19	670.60	881.04	825.00
		AS50 1/2	16	566.79	522.16	562.00
		Flu_Eld	16	638.11	929.43	881.50
		Flu_Yng	19	1366.02	966.33	1474.00
	B/Malaysia	AS03 1/4	21	679.05	4150.67	980.00
		AS03 1/2	18	807.74	629.48	814.00
		AS03 1/1	20	807.96	901.44	801.00
		AS25 1/4	17	416.48	442.15	417.00
		AS25 1/2	21	774.07	452.40	792.00
		AS25 1/1	21	423.03	839.74	803.00
		AS50 1/4	19	582.68	429.62	617.00

		AS50 1/2	16	588.22	334.48	600.50
		Flu_Eld	16	742.01	481.80	785.50
		Flu_Yng	19	1304.54	1096.30	1409.00
CD4-CD40L	A/Solomon Islands	AS03 1/4	21	348.06	342.53	387.00
		AS03 1/2	18	319.80	403.11	520.50
		AS03 1/1	20	622.84	626.39	560.50
		AS25 1/4	17	361.05	490.66	447.00
		AS25 1/2	21	425.72	346.49	662.00
		AS25 1/1	21	471.70	566.40	650.00
		AS50 1/4	19	353.82	432.84	484.00
		AS50 1/2	16	234.90	304.83	363.00
		Flu_Eld	16	690.69	642.61	549.00
		Flu_Yng	19	999.02	831.24	1197.00
	A/Wisconsin	AS03 1/4	21	733.96	397.17	846.00
		AS03 1/2	18	576.04	543.29	831.00
		AS03 1/1	20	682.43	823.68	896.50
		AS25 1/4	17	439.97	825.94	406.00
		AS25 1/2	21	680.00	607.45	675.00
		AS25 1/1	21	683.28	761.14	1069.00
		AS50 1/4	19	623.11	800.89	767.00
		AS50 1/2	16	554.83	502.42	525.50
		Flu_Eld	16	625.97	924.73	828.00
		Flu_Yng	19	1268.21	889.54	1338.00
	B/Malaysia	AS03 1/4	21	621.50	3427.50	881.00
		AS03 1/2	18	764.21	613.38	803.50
		AS03 1/1	20	779.35	887.41	793.00
		AS25 1/4	17	394.05	415.93	417.00
		AS25 1/2	21	743.85	425.01	722.00
		AS25 1/1	21	414.76	732.26	803.00
		AS50 1/4	19	592.52	424.79	596.00
		AS50 1/2	16	537.41	351.86	600.50
		Flu_Eld	16	679.16	486.34	767.00
		Flu_Yng	19	1260.62	1067.54	1342.00
CD4-IFN γ	A/Solomon Islands	AS03 1/4	21	244.53	325.64	330.00
		AS03 1/2	18	375.03	308.38	341.00
		AS03 1/1	20	392.18	500.72	381.50
		AS25 1/4	17	280.73	402.63	257.00
		AS25 1/2	21	261.43	263.15	359.00
		AS25 1/1	21	338.11	488.06	493.00
		AS50 1/4	19	271.38	373.04	340.00
		AS50 1/2	16	136.97	262.56	292.00
		Flu_Eld	16	445.44	577.53	399.00
		Flu_Yng	19	867.78	658.04	932.00
	A/Wisconsin	AS03 1/4	21	492.75	320.15	526.00
		AS03 1/2	18	476.37	416.85	531.50
		AS03 1/1	20	548.14	557.60	618.00
		AS25 1/4	17	372.77	618.70	289.00
		AS25 1/2	21	399.91	481.00	445.00
		AS25 1/1	21	325.70	547.57	670.00
		AS50 1/4	19	523.69	683.65	601.00
		AS50 1/2	16	374.66	407.51	414.00
		Flu_Eld	16	467.74	807.28	508.00
		Flu_Yng	19	971.26	783.42	1046.00
	B/Malaysia	AS03 1/4	21	522.75	3348.47	630.00

		AS03 1/2	18	510.43	462.45	672.00
		AS03 1/1	20	457.89	774.10	452.00
		AS25 1/4	17	253.06	234.64	337.00
		AS25 1/2	21	411.84	384.77	381.00
		AS25 1/1	21	240.48	567.12	468.00
		AS50 1/4	19	361.94	357.95	328.00
		AS50 1/2	16	360.90	250.90	411.00
		Flu_Eld	16	458.80	456.80	469.00
		Flu_Yng	19	1073.05	935.35	1112.00
CD4-IL2	A/Solomon Islands	AS03 1/4	21	316.88	297.00	439.00
		AS03 1/2	18	314.96	372.22	478.00
		AS03 1/1	20	558.83	549.83	599.50
		AS25 1/4	17	304.00	404.11	379.00
		AS25 1/2	21	368.31	348.92	583.00
		AS25 1/1	21	400.05	505.26	562.00
		AS50 1/4	19	304.33	467.47	349.00
		AS50 1/2	16	175.36	258.68	254.00
		Flu_Eld	16	691.47	597.60	579.00
		Flu_Yng	19	859.06	642.57	1012.00
	A/Wisconsin	AS03 1/4	21	579.40	330.85	652.00
		AS03 1/2	18	426.54	422.19	622.50
		AS03 1/1	20	529.59	677.44	817.00
		AS25 1/4	17	480.46	667.59	368.00
		AS25 1/2	21	603.02	608.61	668.00
		AS25 1/1	21	551.29	712.29	837.00
		AS50 1/4	19	489.69	841.98	742.00
		AS50 1/2	16	339.94	440.33	510.00
		Flu_Eld	16	700.87	861.25	725.00
		Flu_Yng	19	1011.95	565.94	1309.00
	B/Malaysia	AS03 1/4	21	549.00	2767.21	748.00
		AS03 1/2	18	617.40	602.01	709.50
		AS03 1/1	20	698.16	823.21	616.00
		AS25 1/4	17	315.90	393.50	362.00
		AS25 1/2	21	672.69	432.34	754.00
		AS25 1/1	21	373.28	680.43	673.00
		AS50 1/4	19	518.17	374.93	563.00
		AS50 1/2	16	345.05	300.46	500.00
		Flu_Eld	16	612.61	455.63	669.50
		Flu_Yng	19	1119.01	801.11	1118.00
CD4-TNFα	A/Solomon Islands	AS03 1/4	21	280.19	284.35	497.00
		AS03 1/2	18	188.48	325.58	358.00
		AS03 1/1	20	382.50	490.32	482.50
		AS25 1/4	17	200.30	422.18	260.00
		AS25 1/2	21	263.40	301.07	506.00
		AS25 1/1	21	350.38	473.03	341.00
		AS50 1/4	19	254.19	373.61	382.00
		AS50 1/2	16	228.89	247.41	289.00
		Flu_Eld	16	533.13	517.19	484.00
		Flu_Yng	19	730.49	549.49	892.00
	A/Wisconsin	AS03 1/4	21	722.29	288.16	778.00
		AS03 1/2	18	600.27	472.44	656.00
		AS03 1/1	20	626.23	655.14	790.00
		AS25 1/4	17	395.86	758.84	390.00
		AS25 1/2	21	599.10	496.66	567.00

		AS25 1/1	21	512.38	740.10	771.00
		AS50 1/4	19	601.79	703.08	655.00
		AS50 1/2	16	561.14	451.82	505.50
		Flu_Eld	16	521.03	873.58	862.50
		Flu_Yng	19	1187.70	734.12	1228.00
	B/Malaysia	AS03 1/4	21	538.21	2445.31	597.00
		AS03 1/2	18	576.09	352.91	517.50
		AS03 1/1	20	408.52	712.70	460.50
		AS25 1/4	17	149.41	359.72	221.00
		AS25 1/2	21	476.90	332.91	511.00
		AS25 1/1	21	160.26	542.67	401.00
		AS50 1/4	19	360.57	367.88	369.00
		AS50 1/2	16	385.22	227.19	423.50
		Flu_Eld	16	505.39	393.49	561.00
		Flu_Yng	19	798.97	716.33	775.00

All doubles: T-cells producing at least 2 cytokines

N = number of subjects with available results

GM = geometric Mean

SD = Standard Deviation

Secondary Outcome Variable(s): Descriptive Statistics on the frequency cytokine-positive CD8 T-cells (per million CD8 T-cells) for each strain at Days 0 and 21 (ATP cohort for immunogenicity CMI)

Test description	Vaccine strain	Group	Timing	N	GM	SD	Median
CD4-All doubles	A/Solomon Islands	AS03 1/4	PRE	23	8.10	135.40	1.00
			PI(D21)	24	7.45	97.10	1.00
		AS03 1/2	PRE	18	12.90	151.71	34.00
			PI(D21)	19	12.20	127.89	14.00
		AS03 1/1	PRE	24	14.46	122.65	65.00
			PI(D21)	25	9.54	116.11	1.00
		AS25 1/4	PRE	24	3.25	53.78	1.00
			PI(D21)	24	5.14	87.63	1.00
		AS25 1/2	PRE	23	3.31	91.60	1.00
			PI(D21)	24	4.87	92.78	1.00
		AS25 1/1	PRE	23	2.31	47.88	1.00
			PI(D21)	23	4.71	49.37	1.00
		AS50 1/4	PRE	22	2.63	98.13	1.00
			PI(D21)	23	9.62	50.39	23.00
		AS50 1/2	PRE	20	6.83	67.42	1.00
			PI(D21)	23	4.76	132.76	1.00
		Flu_Eld	PRE	22	13.81	116.94	64.00
			PI(D21)	23	6.33	91.54	1.00
		Flu_Yng	PRE	18	7.69	91.40	1.00
			PI(D21)	23	2.34	132.36	1.00
	A/Wisconsin	AS03 1/4	PRE	23	9.69	178.06	1.00
			PI(D21)	24	31.08	84.59	71.50
		AS03 1/2	PRE	18	6.81	126.03	1.00
			PI(D21)	19	7.54	234.23	1.00
		AS03 1/1	PRE	24	9.85	344.91	1.00
			PI(D21)	25	9.77	292.05	2.00
		AS25 1/4	PRE	24	3.93	124.78	1.00
			PI(D21)	23	4.15	66.82	1.00
		AS25 1/2	PRE	23	6.67	112.61	1.00
			PI(D21)	24	7.73	139.86	1.00
		AS25 1/1	PRE	23	5.53	169.17	1.00

		AS50 1/4	PI(D21)	23	12.49	189.06	24.00
			PRE	22	8.19	95.91	1.00
		AS50 1/2	PI(D21)	23	16.86	219.38	66.00
			PRE	20	6.73	108.10	1.00
		Flu_Eld	PI(D21)	23	4.99	168.28	1.00
			PRE	22	8.22	153.57	1.00
		Flu_Yng	PI(D21)	23	39.03	123.00	66.00
			PRE	18	9.16	63.84	33.00
			PI(D21)	23	2.00	57.24	1.00
			PRE	23	11.62	200.31	1.00
		AS03 1/2	PI(D21)	22	42.50	296.07	118.00
			PRE	17	15.68	423.52	1.00
CD8-CD40L	B/Malaysia	AS03 1/1	PI(D21)	19	44.96	351.05	115.00
			PRE	24	30.58	282.37	66.00
		AS25 1/4	PI(D21)	25	20.54	188.50	66.00
			PRE	24	10.85	215.20	1.00
		AS25 1/2	PI(D21)	23	8.09	302.34	1.00
			PRE	21	6.74	63.87	1.00
		AS25 1/1	PI(D21)	23	31.02	243.07	66.00
			PRE	23	2.48	44.95	1.00
		AS50 1/4	PI(D21)	23	22.20	183.56	66.00
			PRE	22	26.27	218.28	66.00
		AS50 1/2	PI(D21)	23	60.96	415.86	96.00
			PRE	19	23.57	184.06	73.00
		Flu_Eld	PI(D21)	22	13.39	193.75	27.00
			PRE	21	16.83	232.88	65.00
		Flu_Yng	PI(D21)	23	24.91	153.61	67.00
			PRE	18	11.02	175.35	9.50
			PI(D21)	23	16.20	225.18	44.00
			PRE	23	7.68	76.49	1.00
	A/Solomon Islands	AS03 1/2	PI(D21)	24	3.76	69.81	1.00
			PRE	18	9.18	141.09	1.00
		AS03 1/1	PI(D21)	19	3.41	98.02	1.00
			PRE	24	7.64	81.73	1.00
		AS25 1/4	PI(D21)	25	8.71	75.81	1.00
			PRE	24	2.31	25.28	1.00
		AS25 1/2	PI(D21)	24	2.20	47.58	1.00
			PRE	23	2.75	106.31	1.00
		AS25 1/1	PI(D21)	24	3.22	72.42	1.00
			PRE	23	1.47	26.08	1.00
		AS50 1/4	PI(D21)	23	2.21	42.86	1.00
			PRE	22	2.39	55.56	1.00
		AS50 1/2	PI(D21)	23	3.36	55.81	1.00
			PRE	20	2.94	67.71	1.00
		Flu_Eld	PI(D21)	23	3.45	82.08	1.00
			PRE	22	10.48	95.48	23.00
		Flu_Yng	PI(D21)	23	2.30	53.40	1.00
			PRE	18	2.70	77.94	1.00
			PI(D21)	23	2.97	43.37	1.00
			PRE	23	4.63	51.86	1.00
	A/Wisconsin	AS03 1/2	PI(D21)	24	3.09	45.67	1.00
			PRE	18	2.17	41.97	1.00
		AS03 1/1	PI(D21)	19	5.72	165.77	1.00
			PRE	24	5.20	70.37	1.00

			PI(D21)	25	4.19	52.99	1.00
		AS25 1/4	PRE	24	1.82	70.40	1.00
			PI(D21)	23	3.00	45.24	1.00
		AS25 1/2	PRE	23	2.78	66.95	1.00
			PI(D21)	24	5.72	90.85	1.00
		AS25 1/1	PRE	23	1.47	26.82	1.00
			PI(D21)	23	5.01	88.79	1.00
		AS50 1/4	PRE	22	3.10	43.93	1.00
			PI(D21)	23	5.58	98.17	1.00
		AS50 1/2	PRE	20	2.08	53.94	1.00
			PI(D21)	23	5.17	34.65	1.00
		Flu_Eld	PRE	22	4.55	93.16	1.00
			PI(D21)	23	7.27	43.58	1.00
		Flu_Yng	PRE	18	2.96	99.03	1.00
			PI(D21)	23	2.04	35.04	1.00
	B/Malaysia	AS03 1/4	PRE	23	3.24	54.73	1.00
			PI(D21)	22	2.68	127.60	1.00
		AS03 1/2	PRE	17	7.16	290.97	1.00
			PI(D21)	19	12.06	265.01	8.00
		AS03 1/1	PRE	24	6.53	132.89	1.00
			PI(D21)	25	3.74	115.89	1.00
		AS25 1/4	PRE	24	2.82	87.95	1.00
			PI(D21)	23	4.45	142.55	1.00
		AS25 1/2	PRE	21	2.84	47.37	1.00
			PI(D21)	23	9.13	183.09	1.00
		AS25 1/1	PRE	23	1.66	34.20	1.00
			PI(D21)	23	5.64	138.31	1.00
		AS50 1/4	PRE	22	3.29	76.69	1.00
			PI(D21)	23	8.97	271.08	1.00
		AS50 1/2	PRE	19	5.21	59.00	1.00
			PI(D21)	22	4.47	183.70	1.00
		Flu_Eld	PRE	21	5.52	168.72	1.00
			PI(D21)	23	3.43	72.64	1.00
		Flu_Yng	PRE	18	3.98	95.04	1.00
			PI(D21)	23	9.50	127.97	20.00
CD8-IFN γ	A/Solomon Islands	AS03 1/4	PRE	23	7.38	115.60	1.00
			PI(D21)	24	7.37	84.04	1.00
		AS03 1/2	PRE	18	8.63	157.70	1.00
			PI(D21)	19	9.19	85.93	1.00
		AS03 1/1	PRE	24	10.16	107.21	19.50
			PI(D21)	25	11.15	94.57	20.00
		AS25 1/4	PRE	24	3.99	62.89	1.00
			PI(D21)	24	2.18	51.19	1.00
		AS25 1/2	PRE	23	4.69	90.75	1.00
			PI(D21)	24	3.96	75.52	1.00
		AS25 1/1	PRE	23	1.89	57.50	1.00
			PI(D21)	23	2.03	23.00	1.00
		AS50 1/4	PRE	22	3.04	89.37	1.00
			PI(D21)	23	5.60	50.57	1.00
		AS50 1/2	PRE	20	6.83	63.62	1.00
			PI(D21)	23	3.18	106.55	1.00
		Flu_Eld	PRE	22	8.68	98.54	1.00
			PI(D21)	23	3.25	64.56	1.00
		Flu_Yng	PRE	18	4.59	65.86	1.00

	A/Wisconsin	AS03 1/4	PI(D21)	23	1.59	141.41	1.00
			PRE	23	7.85	103.62	1.00
		AS03 1/2	PI(D21)	24	8.27	78.96	1.00
			PRE	18	3.95	78.12	1.00
		AS03 1/1	PI(D21)	19	8.63	176.22	1.00
			PRE	24	7.61	309.89	1.00
		AS25 1/4	PI(D21)	25	9.89	295.99	2.00
			PRE	24	2.46	120.14	1.00
		AS25 1/2	PI(D21)	23	3.52	66.86	1.00
			PRE	23	5.23	75.71	1.00
		AS25 1/1	PI(D21)	24	6.18	125.90	1.00
			PRE	23	2.51	168.10	1.00
		AS50 1/4	PI(D21)	23	10.28	119.10	1.00
			PRE	22	4.70	53.61	1.00
		AS50 1/2	PI(D21)	23	12.07	140.10	9.00
			PRE	20	4.05	52.57	1.00
		Flu_Eld	PI(D21)	23	4.02	92.71	1.00
			PRE	22	7.23	129.33	1.00
		Flu_Yng	PI(D21)	23	6.94	109.72	1.00
			PRE	18	7.26	64.60	1.00
	B/Malaysia	AS03 1/4	PI(D21)	23	2.21	47.90	1.00
			PRE	23	5.56	99.28	1.00
		AS03 1/2	PI(D21)	22	11.69	129.41	15.00
			PRE	17	10.71	390.44	1.00
		AS03 1/1	PI(D21)	19	17.80	305.22	42.00
			PRE	24	15.15	261.46	61.50
		AS25 1/4	PI(D21)	25	14.44	160.52	39.00
			PRE	24	6.09	157.93	1.00
		AS25 1/2	PI(D21)	23	5.42	269.73	1.00
			PRE	21	10.28	61.17	32.00
		AS25 1/1	PI(D21)	23	14.05	224.41	45.00
			PRE	23	1.69	19.96	1.00
		AS50 1/4	PI(D21)	23	9.75	159.06	1.00
			PRE	22	17.27	129.27	62.00
		AS50 1/2	PI(D21)	23	23.95	323.71	66.00
			PRE	19	17.76	137.26	66.00
		Flu_Eld	PI(D21)	22	18.53	162.45	48.50
			PRE	21	9.94	190.65	1.00
		Flu_Yng	PI(D21)	23	21.99	122.96	66.00
			PRE	18	9.07	168.50	1.00
CD8-IL2	A/Solomon Islands	AS03 1/4	PI(D21)	23	12.44	163.33	1.00
			PRE	24	4.80	63.95	1.00
		AS03 1/2	PI(D21)	18	3.10	27.39	1.00
			PRE	19	4.30	73.39	1.00
		AS03 1/1	PI(D21)	24	5.50	55.47	1.00
			PRE	25	7.50	51.96	1.00
		AS25 1/4	PI(D21)	24	3.97	61.17	1.00
			PRE	24	3.03	42.10	1.00
		AS25 1/2	PI(D21)	23	1.20	13.14	1.00
			PRE	24	1.98	40.41	1.00
		AS25 1/1	PI(D21)	23	2.12	30.13	1.00
			PRE	23	4.86	57.41	1.00
		AS50 1/4	PRE	22	3.28	81.61	1.00

			PI(D21)	23	4.36	36.32	1.00
		AS50 1/2	PRE	20	2.96	40.40	1.00
			PI(D21)	23	5.57	83.12	1.00
		Flu_Eld	PRE	22	4.00	42.26	1.00
			PI(D21)	23	7.30	69.21	1.00
		Flu_Yng	PRE	18	2.67	38.98	1.00
			PI(D21)	23	2.17	44.90	1.00
	A/Wisconsin	AS03 1/4	PRE	23	3.70	113.92	1.00
			PI(D21)	24	12.45	89.54	42.00
		AS03 1/2	PRE	18	3.21	91.01	1.00
			PI(D21)	19	5.93	78.91	1.00
		AS03 1/1	PRE	24	6.13	99.85	1.00
			PI(D21)	25	7.70	64.46	1.00
		AS25 1/4	PRE	24	3.13	61.75	1.00
			PI(D21)	23	3.05	40.35	1.00
		AS25 1/2	PRE	23	2.11	71.74	1.00
			PI(D21)	24	2.97	61.70	1.00
		AS25 1/1	PRE	23	4.05	62.37	1.00
			PI(D21)	23	4.41	109.49	1.00
		AS50 1/4	PRE	22	5.41	65.29	1.00
			PI(D21)	23	10.92	109.83	19.00
		AS50 1/2	PRE	20	6.43	82.32	1.00
			PI(D21)	23	6.18	125.87	1.00
		Flu_Eld	PRE	22	3.75	71.92	1.00
			PI(D21)	23	14.11	81.52	65.00
		Flu_Yng	PRE	18	2.00	23.96	1.00
			PI(D21)	23	2.69	51.22	1.00
	B/Malaysia	AS03 1/4	PRE	23	8.66	147.36	1.00
			PI(D21)	22	17.85	257.14	66.00
		AS03 1/2	PRE	17	4.40	161.85	1.00
			PI(D21)	19	32.92	72.84	89.00
		AS03 1/1	PRE	24	10.05	141.49	15.50
			PI(D21)	25	9.72	118.83	11.00
		AS25 1/4	PRE	24	9.50	106.18	10.50
			PI(D21)	23	4.83	129.69	1.00
		AS25 1/2	PRE	21	2.13	22.15	1.00
			PI(D21)	23	7.60	127.90	1.00
		AS25 1/1	PRE	23	2.66	49.28	1.00
			PI(D21)	23	8.49	137.21	1.00
		AS50 1/4	PRE	22	12.10	182.42	32.00
			PI(D21)	23	17.98	127.27	66.00
		AS50 1/2	PRE	19	17.14	88.20	66.00
			PI(D21)	22	5.19	81.07	1.00
		Flu_Eld	PRE	21	6.41	108.44	1.00
			PI(D21)	23	7.95	75.16	1.00
		Flu_Yng	PRE	18	2.17	64.13	1.00
			PI(D21)	23	12.46	96.16	65.00
CD8-TNF α	A/Solomon Islands	AS03 1/4	PRE	23	5.41	91.54	1.00
			PI(D21)	24	3.79	79.93	1.00
		AS03 1/2	PRE	18	3.26	34.12	1.00
			PI(D21)	19	12.15	70.97	66.00
		AS03 1/1	PRE	24	8.71	71.14	1.00
			PI(D21)	25	2.76	117.87	1.00
		AS25 1/4	PRE	24	2.59	42.20	1.00

			PI(D21)	24	5.85	65.60	1.00	
		AS25 1/2	PRE	23	2.58	39.14	1.00	
			PI(D21)	24	2.68	61.45	1.00	
		AS25 1/1	PRE	23	2.28	45.26	1.00	
			PI(D21)	23	3.78	51.36	1.00	
		AS50 1/4	PRE	22	2.18	33.72	1.00	
			PI(D21)	23	5.33	36.95	1.00	
		AS50 1/2	PRE	20	5.63	58.18	1.00	
			PI(D21)	23	6.03	110.26	1.00	
		Flu_Eld	PRE	22	3.94	52.44	1.00	
			PI(D21)	23	4.35	64.50	1.00	
		Flu_Yng	PRE	18	4.33	81.83	1.00	
			PI(D21)	23	1.91	131.67	1.00	
		A/Wisconsin	AS03 1/4	PRE	23	5.04	145.40	1.00
				PI(D21)	24	14.64	98.80	64.00
			AS03 1/2	PRE	18	3.70	138.04	1.00
				PI(D21)	19	5.75	118.21	1.00
			AS03 1/1	PRE	24	5.31	338.73	1.00
	PI(D21)			25	5.74	278.42	1.00	
	AS25 1/4		PRE	24	3.70	67.70	1.00	
			PI(D21)	23	3.47	65.17	1.00	
	AS25 1/2		PRE	23	8.64	86.13	1.00	
			PI(D21)	24	5.60	66.01	1.00	
	AS25 1/1		PRE	23	9.54	187.33	1.00	
			PI(D21)	23	12.32	188.66	24.00	
	AS50 1/4		PRE	22	5.96	128.54	1.00	
			PI(D21)	23	11.29	211.80	1.00	
	AS50 1/2		PRE	20	10.06	78.63	28.00	
			PI(D21)	23	8.52	135.47	1.00	
	Flu_Eld		PRE	22	3.93	93.43	1.00	
			PI(D21)	23	16.28	142.20	66.00	
	Flu_Yng		PRE	18	3.41	64.37	1.00	
			PI(D21)	23	2.52	46.95	1.00	
	B/Malaysia		AS03 1/4	PRE	23	11.49	167.40	3.00
				PI(D21)	22	28.50	261.61	66.00
			AS03 1/2	PRE	17	11.28	215.17	1.00
				PI(D21)	19	13.76	122.97	53.00
		AS03 1/1	PRE	24	18.47	194.16	66.00	
			PI(D21)	25	9.28	142.76	1.00	
		AS25 1/4	PRE	24	8.77	177.85	1.00	
			PI(D21)	23	9.21	224.57	1.00	
		AS25 1/2	PRE	21	6.77	50.82	1.00	
			PI(D21)	23	15.20	160.37	66.00	
		AS25 1/1	PRE	23	2.67	37.22	1.00	
			PI(D21)	23	9.02	96.93	1.00	
		AS50 1/4	PRE	22	26.25	172.19	66.00	
			PI(D21)	23	27.84	355.89	77.00	
		AS50 1/2	PRE	19	23.27	109.52	66.00	
PI(D21)			22	15.64	126.07	45.00		
Flu_Eld		PRE	21	14.97	169.37	24.00		
		PI(D21)	23	19.42	124.13	66.00		
Flu_Yng	PRE	18	9.07	123.64	1.00			
	PI(D21)	23	8.57	151.66	1.00			

All doubles: T-cells producing at least 2 cytokines

N = number of subjects with available results
 GM = geometric Mean
 SD = Standard Deviation
 PRE = pre-vaccination dose 1 (Day 0)
 PI(D21) = post-vaccination dose 1 (Day 21)

Secondary Outcome Variable(s): Descriptive Statistics on the frequency of cytokine-positive CD8 T-cells (per million CD8 T-cells) for each strain at Day 180 (ATP cohort for persistence for CMI)

Test description	Vaccine strain	Group	N	GM	SD	Median
CD8-ALL DOUBLES	A/Solomon Islands	AS03 1/4	21	2.57	89.78	1.00
		AS03 1/2	18	14.64	96.62	68.50
		AS03 1/1	20	3.61	143.10	1.00
		AS25 1/4	17	4.75	74.09	1.00
		AS25 1/2	21	3.05	107.06	1.00
		AS25 1/1	20	1.24	15.43	1.00
		AS50 1/4	19	2.64	47.18	1.00
		AS50 1/2	16	4.81	90.76	1.00
		Flu_Eld	16	7.32	115.74	1.00
		Flu_Yng	19	5.64	98.76	1.00
	A/Wisconsin	AS03 1/4	21	21.14	506.65	76.00
		AS03 1/2	18	9.63	110.40	1.00
		AS03 1/1	20	18.10	367.31	68.00
		AS25 1/4	17	16.14	132.83	72.00
		AS25 1/2	21	20.72	412.35	69.00
		AS25 1/1	20	21.73	368.70	69.50
		AS50 1/4	19	21.00	327.24	69.00
		AS50 1/2	15	11.95	384.28	1.00
		Flu_Eld	16	10.44	226.57	1.00
		Flu_Yng	19	3.13	186.12	1.00
	B/Malaysia	AS03 1/4	20	9.92	111.75	4.00
		AS03 1/2	18	7.10	132.35	1.00
		AS03 1/1	19	12.14	319.23	2.00
		AS25 1/4	17	9.61	157.68	1.00
		AS25 1/2	21	25.48	138.45	68.00
		AS25 1/1	20	9.18	143.21	1.00
		AS50 1/4	19	12.73	460.97	69.00
		AS50 1/2	15	4.71	115.31	1.00
		Flu_Eld	16	6.47	83.62	1.00
		Flu_Yng	19	7.96	132.07	1.00
CD8-CD40L	A/Solomon Islands	AS03 1/4	21	2.92	53.08	1.00
		AS03 1/2	18	12.64	119.84	35.50
		AS03 1/1	20	2.95	97.98	1.00
		AS25 1/4	17	3.18	74.24	1.00
		AS25 1/2	21	3.97	69.10	1.00
		AS25 1/1	20	1.93	31.31	1.00
		AS50 1/4	19	2.70	59.56	1.00
		AS50 1/2	16	4.89	86.67	1.00
		Flu_Eld	16	8.74	100.11	1.50
		Flu_Yng	19	3.94	40.79	1.00
	A/Wisconsin	AS03 1/4	21	18.75	312.61	72.00
		AS03 1/2	18	7.79	60.25	1.00
		AS03 1/1	20	10.73	230.49	1.00
		AS25 1/4	17	15.32	145.70	68.00
		AS25 1/2	21	9.60	232.78	1.00
		AS25 1/1	20	8.57	321.14	1.00

	B/Malaysia	AS50 1/4	19	13.90	118.80	70.00
		AS50 1/2	15	6.00	315.87	1.00
		Flu_Eld	16	6.46	135.88	1.00
		Flu_Yng	19	3.43	66.51	1.00
		AS03 1/4	20	5.79	103.71	1.00
		AS03 1/2	18	5.64	75.90	1.00
		AS03 1/1	19	10.61	125.46	1.00
		AS25 1/4	17	7.48	92.38	1.00
		AS25 1/2	21	8.46	105.02	1.00
		AS25 1/1	20	6.10	113.43	1.00
		AS50 1/4	19	3.77	59.02	1.00
		AS50 1/2	15	2.75	73.05	1.00
		Flu_Eld	16	3.63	81.37	1.00
		Flu_Yng	19	3.78	95.38	1.00
CD8-IFN γ	A/Solomon Islands	AS03 1/4	21	2.00	54.66	1.00
		AS03 1/2	18	3.12	124.76	1.00
		AS03 1/1	20	3.13	50.16	1.00
		AS25 1/4	17	3.89	53.23	1.00
		AS25 1/2	21	1.90	35.38	1.00
		AS25 1/1	20	3.12	47.02	1.00
		AS50 1/4	19	3.07	31.51	1.00
		AS50 1/2	16	3.11	45.39	1.00
		Flu_Eld	16	2.36	55.08	1.00
		Flu_Yng	19	2.65	79.58	1.00
	A/Wisconsin	AS03 1/4	21	4.21	167.18	1.00
		AS03 1/2	18	2.68	42.60	1.00
		AS03 1/1	20	2.32	92.50	1.00
		AS25 1/4	17	2.89	43.98	1.00
		AS25 1/2	21	2.50	53.46	1.00
		AS25 1/1	20	2.53	46.46	1.00
		AS50 1/4	19	2.39	154.17	1.00
		AS50 1/2	15	3.67	78.90	1.00
		Flu_Eld	16	1.97	157.41	1.00
		Flu_Yng	19	2.72	125.70	1.00
	B/Malaysia	AS03 1/4	20	10.63	76.06	37.50
		AS03 1/2	18	3.72	66.40	1.00
		AS03 1/1	19	6.46	183.07	1.00
		AS25 1/4	17	6.19	170.54	1.00
		AS25 1/2	21	10.24	49.87	67.00
		AS25 1/1	20	4.96	55.70	1.00
		AS50 1/4	19	8.54	430.43	1.00
		AS50 1/2	15	2.56	40.61	1.00
		Flu_Eld	16	4.12	49.87	1.00
		Flu_Yng	19	5.33	182.33	1.00
CD8-IL2	A/Solomon Islands	AS03 1/4	21	1.97	64.78	1.00
		AS03 1/2	18	10.49	74.37	34.50
		AS03 1/1	20	2.82	105.05	1.00
		AS25 1/4	17	3.36	44.53	1.00
		AS25 1/2	21	3.76	68.56	1.00
		AS25 1/1	20	1.89	25.41	1.00
		AS50 1/4	19	4.31	70.92	1.00
		AS50 1/2	16	4.89	86.67	1.00
		Flu_Eld	16	4.93	111.36	1.00
		Flu_Yng	19	7.15	75.19	1.00

Secondary Outcome Variable(s): Number (percentage) of subjects reporting solicited local symptoms reported during the 7-day (Days 0-6) post-vaccination period using new grading for quantifiable symptoms (Total Vaccinated cohort)

		AS03 1/4 Group					AS03 1/2 Group				
					95 % CI					95 % CI	
Symptom	Intensity	N	n	%	LL	UL	N	n	%	LL	UL
Ecchymosis	>20 mm	201	3	1.5	0.3	4.3	201	1	0.5	0.0	2.7
	> 100 mm	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Pain	Any	201	68	33.8	27.3	40.8	201	82	40.8	33.9	47.9
	Grade 3	201	1	0.5	0.0	2.7	201	1	0.5	0.0	2.7
Redness	>20 mm	201	15	7.5	4.2	12.0	201	16	8.0	4.6	12.6
	>100 mm	201	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7
Swelling	>20 mm	201	13	6.5	3.5	10.8	201	12	6.0	3.1	10.2
	>100 mm	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
		AS03 1/1 Group					AS25 1/4 Group				
Ecchymosis	>20 mm	201	5	2.5	0.8	5.7	201	1	0.5	0.0	2.7
	>100 mm	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Pain	Any	201	111	55.2	48.1	62.2	201	84	41.8	34.9	48.9
	Grade 3	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Redness	>20 mm	201	37	18.4	13.3	24.5	201	12	6.0	3.1	10.2
	>100 mm	201	3	1.5	0.3	4.3	201	1	0.5	0.0	2.7
Swelling	>20 mm	201	25	12.4	8.2	17.8	201	13	6.5	3.5	10.8
	> 100 mm	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
		AS25 1/2 Group					AS25 1/1 Group				
Ecchymosis	>20 mm	198	2	1.0	0.1	3.6	197	2	1.0	0.1	3.6
	>100 mm	198	0	0.0	0.0	1.8	197	0	0.0	0.0	1.9
Pain	Any	198	91	46.0	38.9	53.2	197	119	60.4	53.2	67.3
	Grade 3	198	1	0.5	0.0	2.8	197	2	1.0	0.1	3.6
Redness	>20 mm	198	33	16.7	11.8	22.6	197	36	18.3	13.1	24.4
	>100 mm	198	1	0.5	0.0	2.8	197	2	1.0	0.1	3.6
Swelling	>20 mm	198	18	9.1	5.5	14.0	197	23	11.7	7.5	17.0
	>100 mm	198	1	0.5	0.0	2.8	197	1	0.5	0.0	2.8
		AS50 1/4 Group					AS50 1/2Group				
Ecchymosis	>20 mm	198	4	2.0	0.6	5.1	198	2	1.0	0.1	3.6
	>100 mm	198	0	0.0	0.0	1.8	198	0	0.0	0.0	1.8
Pain	Any	198	93	47.0	39.9	54.2	198	106	53.5	46.3	60.6
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
Redness	>20 mm	198	18	9.1	5.5	14.0	198	34	17.2	12.2	23.2
	>100 mm	198	0	0.0	0.0	1.8	198	2	1.0	0.1	3.6
Swelling	>20 mm	198	11	5.6	2.8	9.7	198	25	12.6	8.3	18.1
	>100 mm	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
		Flu_Eld Group					Flu_Yng Group				
Ecchymosis	>20 mm	200	3	1.5	0.3	4.3	201	0	0.0	0.0	1.8
	>100 mm	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Pain	Any	200	32	16.0	11.2	21.8	201	93	46.3	39.2	53.4
	Grade 3	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Redness	>20 mm	200	5	2.5	0.8	5.7	201	2	1.0	0.1	3.5
	> 100 mm	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
Swelling	>20 mm	200	5	2.5	0.8	5.7	201	2	1.0	0.1	3.5
	> 100	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8

N= number of subjects with the documented dose

n/%= number/percentage of subjects reporting at least once the symptom

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

Any: occurrence of any local symptom regardless of their intensity grade

Grade 3 Pain: considerable pain at rest, that prevented normal everyday activities

Secondary Outcome Variable(s): Number of days with any grade local symptoms during the 7-day post-vaccination period using New GSK grading for quantifiable symptoms (Total vaccinated cohort)

Solicited symptom	Group	N	Mean	Median
Ecchymosis	AS03 1/4	3	4.3	5.0
	AS03 1/2	1	6.0	6.0
	AS03 1/1	5	5.4	6.0
	AS25 1/4	1	2.0	2.0
	AS25 1/2	2	2.5	2.5
	AS25 1/1	2	3.0	3.0
	AS50 1/4	4	3.0	3.0
	AS50 1/2	2	3.0	3.0
	Flu_Eld	3	5.3	5.0
Pain	AS03 1/4	68	2.3	2.0
	AS03 1/2	82	2.3	2.0
	AS03 1/1	111	2.6	2.0
	AS25 1/4	84	2.3	2.0
	AS25 1/2	91	2.2	2.0
	AS25 1/1	119	2.5	2.0
	AS50 1/4	93	2.1	2.0
	AS50 1/2	106	2.5	2.0
	Flu_Eld	32	2.1	2.0
	Flu_Yng	93	2.2	2.0
Redness	AS03 1/4	14	2.2	1.5
	AS03 1/2	16	2.4	2.0
	AS03 1/1	35	3.1	3.0
	AS25 1/4	11	3.1	3.0
	AS25 1/2	33	2.4	2.0
	AS25 1/1	36	3.2	3.0
	AS50 1/4	18	2.0	2.0
	AS50 1/2	34	2.6	3.0
	Flu_Eld	5	2.0	2.0
	Flu_Yng	2	1.0	1.0
Swelling	AS03 1/4	12	2.0	2.0
	AS03 1/2	12	2.2	2.0
	AS03 1/1	24	3.1	2.5
	AS25 1/4	12	2.3	1.0
	AS25 1/2	17	2.8	2.0
	AS25 1/1	23	3.3	3.0
	AS50 1/4	11	2.0	2.0
	AS50 1/2	25	2.6	2.0
	Flu_Eld	5	2.4	1.0
	Flu_Yng	2	1.5	1.5

N = number of subjects with the symptom

Secondary Outcome variable(s): Number (percentage) of subjects reporting solicited general symptoms reported during the 7-day (Days 0-6) post-vaccination period (Total Vaccinated cohort)

		AS03 1/4 Group					AS03 1/2 Group				
					95 % CI					95 % CI	
Symptom	Intensity/ relationship	N	n	%	LL	UL	N	n	%	LL	UL
Arthralgia	Any	201	15	7.5	4.2	12.0	201	23	11.4	7.4	16.7
	Grade 3	201	3	1.5	0.3	4.3	201	1	0.5	0.0	2.7
	Related	201	11	5.5	2.8	9.6	201	15	7.5	4.2	12.0
Fatigue	Any	201	34	16.9	12.0	22.8	201	35	17.4	12.4	23.4
	Grade 3	201	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7

	Related	201	21	10.4	6.6	15.5	201	24	11.9	7.8	17.2
Headache	Any	201	22	10.9	7.0	16.1	201	38	18.9	13.7	25.0
	Grade 3	201	2	1.0	0.1	3.5	201	1	0.5	0.0	2.7
	Related	201	14	7.0	3.9	11.4	201	23	11.4	7.4	16.7
Myalgia	Any	201	20	1.0	6.2	14.9	201	35	17.4	12.4	23.4
	Grade 3	201	1	0.5	0.0	2.7	201	1	0.5	0.0	2.7
	Related	201	13	6.5	3.5	10.8	201	29	14.4	9.9	20.1
Nausea	Any	201	10	5.0	2.4	9.0	201	12	6.0	3.1	10.2
	Grade 3	201	0	0.0	0.0	1.8	201	2	1.0	0.1	3.5
	Related	201	6	3.0	1.1	6.4	201	9	4.5	2.1	8.3
Shivering	Any	201	13	6.5	3.5	10.8	201	18	9.0	5.4	13.8
	Grade 3	201	1	0.5	0.0	2.7	201	3	1.5	0.3	4.3
	Related	201	9	4.5	2.1	8.3	201	14	7.0	3.9	11.4
Fever (Axillary)	≥38°C	201	1	0.5	0.0	2.7	201	1	0.5	0.0	2.7
	>40°C	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	201	1	0.5	0.0	2.7	201	1	0.5	0.0	2.7
		AS03 1/1 Group					AS25 1/4 Group				
Arthralgia	Any	201	36	17.9	12.9	23.9	201	16	8.0	4.6	12.6
	Grade 3	201	2	1.0	0.1	3.5	201	1	0.5	0.0	2.7
	Related	201	30	14.9	10.3	20.6	201	10	5.0	2.4	9.0
Fatigue	Any	201	54	26.9	20.9	33.6	201	35	17.4	12.4	23.4
	Grade 3	201	3	1.5	0.3	4.3	201	0	0.0	0.0	1.8
	Related	201	39	19.4	14.2	25.6	201	20	10.0	6.2	14.9
Headache	Any	201	47	23.4	17.7	29.9	201	35	17.4	12.4	23.4
	Grade 3	201	2	1.0	0.1	3.5	201	0	0.0	0.0	1.8
	Related	201	28	13.9	9.5	19.5	201	18	9.0	5.4	13.8
Myalgia	Any	201	57	28.4	22.2	35.1	201	30	14.9	10.3	20.6
	Grade 3	201	2	1.0	0.1	3.5	201	1	0.5	0.0	2.7
	Related	201	46	22.9	17.3	29.3	201	24	11.9	7.8	17.2
Nausea	Any	201	19	9.5	5.8	14.4	201	10	5.0	2.4	9.0
	Grade 3	201	1	0.5	0.0	2.7	201	0	0.0	0.0	1.8
	Related	201	10	5.0	2.4	9.0	201	5	2.5	0.8	5.7
Shivering	Any	201	37	18.4	13.3	24.5	201	26	12.9	8.6	18.4
	Grade 3	201	2	1.0	0.1	3.5	201	0	0.0	0.0	1.8
	Related	201	26	13.9	8.6	18.4	201	21	10.4	6.6	15.5
Fever (Axillary)	≥38°C	201	3	1.5	0.3	4.3	201	2	1.0	0.1	3.5
	>40°C	201	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	201	3	1.5	0.3	4.3	201	2	1.0	0.1	3.5
		AS25 1/2 Group					AS25 1/1 Group				
Arthralgia	Any	198	21	10.6	6.7	15.8	198	45	22.7	17.1	29.2
	Grade 3	198	0	0.0	0.0	1.8	198	2	1.0	0.1	3.6
	Related	198	16	8.1	4.7	12.8	198	28	14.1	9.6	19.8
Fatigue	Any	198	46	23.2	17.5	29.7	198	55	27.8	21.7	34.6
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	35	17.7	12.6	23.7	198	38	19.2	14.0	25.4
Headache	Any	198	39	19.7	14.4	25.9	198	55	27.8	21.7	34.6
	Grade 3	198	0	0.0	0.0	1.8	198	4	2.0	0.6	5.1
	Related	198	24	12.1	7.9	17.5	198	27	13.6	9.2	19.2
Myalgia	Any	198	47	23.7	18.0	30.3	198	66	33.3	26.8	40.4
	Grade 3	198	1	0.5	0.0	2.8	198	3	1.5	0.3	4.4
	Related	198	36	18.2	13.1	24.3	198	46	23.2	17.5	29.7
Nausea	Any	198	13	6.6	3.5	11.0	198	18	9.1	5.5	14.0
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	8	4.0	1.8	7.8	198	9	4.5	2.1	8.5

Shivering	Any	198	18	9.1	5.5	14.0	198	43	21.7	16.2	28.1
	Grade 3	198	0	0.0	0.0	1.8	198	4	2.0	0.6	5.1
	Related	198	7	3.5	1.4	7.1	198	27	13.6	9.2	19.2
Fever (Axillary)	≥38°C	198	2	1.0	0.1	3.6	198	6	3.0	1.1	6.5
	>40°C	198	0	0.0	0.0	1.8	198	0	0.0	0.0	1.8
	Related	198	1	0.5	0.0	2.8	198	5	2.5	0.8	5.8
		AS50 1/4 Group					AS50 1/2Group				
Arthralgia	Any	198	28	14.1	9.6	19.8	198	35	17.7	12.6	23.7
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	20	10.1	6.3	15.2	198	25	12.6	8.3	18.1
Fatigue	Any	198	38	19.2	14.0	25.4	198	63	31.8	25.4	38.8
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	25	12.6	8.3	18.1	198	35	17.7	12.6	23.7
Headache	Any	198	36	18.2	13.1	24.3	198	48	24.2	18.4	30.8
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	15	7.6	4.3	12.2	198	27	13.6	9.2	19.2
Myalgia	Any	198	46	23.2	17.5	29.7	198	56	28.3	22.1	35.1
	Grade 3	198	0	0.0	0.0	1.8	198	2	1.0	0.1	3.6
	Related	198	34	17.2	12.2	23.2	198	44	22.2	16.6	28.7
Nausea	Any	198	8	4.0	1.8	7.8	198	14	7.1	3.9	11.6
	Grade 3	198	0	0.0	0.0	1.8	198	1	0.5	0.0	2.8
	Related	198	4	2.0	0.6	5.1	198	10	5.1	2.4	9.1
Shivering	Any	198	17	8.6	5.1	13.4	198	31	15.7	10.9	21.5
	Grade 3	198	0	0.0	0.0	1.8	198	2	1.0	0.1	3.6
	Related	198	12	6.1	3.2	10.3	198	21	10.6	6.7	15.8
Fever (Axillary)	≥38°C	198	3	1.5	0.3	4.4	198	6	3.0	1.1	6.5
	>40°C	198	0	0.0	0.0	1.8	198	0	0.0	0.0	1.8
	Related	198	3	1.5	0.3	4.4	198	4	2.0	0.6	5.1
		Flu_Eld Group					Flu_Yng Group				
Arthralgia	Any	200	16	8.0	4.6	12.7	201	12	6.0	3.1	10.2
	Grade 3	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	200	9	4.5	2.1	8.4	201	9	4.5	2.1	8.3
Fatigue	Any	200	24	12.0	7.8	17.3	201	41	20.4	15.1	26.6
	Grade 3	200	0	0.0	0.0	1.8	201	2	1.0	0.1	3.5
	Related	200	16	8.0	4.6	12.7	201	30	14.9	10.3	20.6
Headache	Any	200	23	11.5	7.4	16.8	201	45	22.4	16.8	28.8
	Grade 3	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	200	20	10.0	6.2	15.0	201	30	14.9	10.3	20.6
Myalgia	Any	200	19	9.5	5.8	14.4	201	40	19.9	14.6	26.1
	Grade 3	200	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7
	Related	200	15	7.5	4.3	12.1	201	33	16.4	11.6	22.3
Nausea	Any	200	6	3.0	1.1	6.4	201	13	6.5	3.5	10.8
	Grade 3	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	200	4	2.0	0.5	5.0	201	11	5.5	2.8	9.6
Shivering	Any	200	8	4.0	1.7	7.7	201	21	10.4	6.6	15.5
	Grade 3	200	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7
	Related	200	6	3.0	1.1	6.4	201	16	8.0	4.6	12.6
Fever (Axillary)	≥38°C	200	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7
	>40°C	200	0	0.0	0.0	1.8	201	0	0.0	0.0	1.8
	Related	200	0	0.0	0.0	1.8	201	1	0.5	0.0	2.7

N= number of subjects with the documented dose
n/%=number/percentage of the subjects reporting at least once the symptom
95%CI95% CI= exact 95% confidence interval; LL = lower limit, UL = upper limit
Any: occurrence of any general symptom regardless of their intensity grade or relationship to vaccination.

Grade 3 Symptoms: symptoms that prevented normal activity				
Related = general symptom assessed by the investigators as causally related to the study vaccination				
Secondary Outcome variable(s): Number of days with any grade of general symptoms during the 7-day post-vaccination period (Total vaccinated cohort)				
Solicited symptom	Group	N	Mean	Median
Arthralgia	AS03 1/4	15	3.8	3.0
	AS03 1/2	23	2.7	2.0
	AS03 1/1	36	2.6	2.0
	AS25 1/4	16	2.8	2.0
	AS25 1/2	21	2.1	2.0
	AS25 1/1	45	2.5	2.0
	AS50 1/4	28	2.3	2.0
	AS50 1/2	35	2.6	2.0
	Flu_Eld	16	3.2	3.0
	Flu_Yng	12	2.5	2.0
Fatigue	AS03 1/4	34	2.4	2.0
	AS03 1/2	35	2.2	2.0
	AS03 1/1	54	2.3	2.0
	AS25 1/4	35	2.0	1.0
	AS25 1/2	46	2.0	2.0
	AS25 1/1	55	1.9	2.0
	AS50 1/4	38	2.4	2.0
	AS50 1/2	63	2.1	2.0
	Flu_Eld	24	2.5	2.0
	Flu_Yng	41	2.4	2.0
Headache	AS03 1/4	22	2.2	1.5
	AS03 1/2	38	1.6	1.0
	AS03 1/1	47	2.3	2.0
	AS25 1/4	35	2.0	1.0
	AS25 1/2	39	1.9	1.0
	AS25 1/1	55	1.8	2.0
	AS50 1/4	36	1.9	1.5
	AS50 1/2	48	1.9	1.0
	Flu_Eld	23	1.9	1.0
	Flu_Yng	45	2.2	2.0
Myalgia	AS03 1/4	20	2.7	2.0
	AS03 1/2	35	2.5	2.0
	AS03 1/1	57	2.5	2.0
	AS25 1/4	30	2.1	2.0
	AS25 1/2	47	2.0	2.0
	AS25 1/1	66	2.3	2.0
	AS50 1/4	46	2.2	2.0
	AS50 1/2	56	2.4	2.0
	Flu_Eld	19	2.7	2.0
	Flu_Yng	40	2.1	2.0
Nausea	AS03 1/4	10	1.8	1.5
	AS03 1/2	12	1.5	1.0
	AS03 1/1	19	1.5	1.0
	AS25 1/4	10	1.7	1.0
	AS25 1/2	13	1.8	1.0
	AS25 1/1	18	1.9	1.5
	AS50 1/4	8	2.1	1.0
	AS50 1/2	14	2.1	1.0
	Flu_Eld	6	1.7	1.5

	Flu_Yng	13	1.9	1.0
Shivering	AS03 1/4	13	1.5	1.0
	AS03 1/2	18	1.8	1.0
	AS03 1/1	37	1.9	1.0
	AS25 1/4	26	1.7	1.0
	AS25 1/2	18	1.7	1.0
	AS25 1/1	43	1.5	1.0
	AS50 1/4	17	2.1	1.0
	AS50 1/2	31	1.9	1.0
	Flu_Eld	8	2.6	2.5
	Flu_Yng	21	2.0	1.0
Fever	AS03 1/4	4	1.0	1.0
	AS03 1/2	3	2.0	2.0
	AS03 1/1	9	1.8	1.0
	AS25 1/4	4	1.3	1.0
	AS25 1/2	3	1.0	1.0
	AS25 1/1	14	1.4	1.0
	AS50 1/4	6	2.0	1.0
	AS50 1/2	12	1.6	1.0
	Flu_Yng	1	2.0	2.0

N = number of subjects with the symptom

Secondary Outcome variable(s): Number (%) of subjects with adverse events that resulted in a medically attended visit between Day 0 and Day 20 after vaccination (Total vaccinated cohort)

Adverse events resulting in medically attended visit	AS03_1_4 Group N = 204	AS03_1_2 Group N = 202	AS03_1_1 Group N = 202	AS25_1_4 Group N = 202	AS25_1_2 Group N = 199	AS25_1_1 Group N = 198
Subjects with any AE(s), n (%)	15 (7.4)	10 (5.0)	19 (9.4)	15 (7.4)	16 (8.0)	14 (7.1)
Subjects with grade 3 AE(s)*, n (%)	0 (0.0)	2 (1.0)	4 (2.0)	3 (1.5)	0 (0.0)	4 (2.0)
Subjects with related AE(s)**, n (%)	0 (0.0)	0 (0.0)	4 (2.0)	0 (0.0)	1 (0.5)	2 (1.0)
Hypertension	-	-	1 (0.5)	-	-	3 (1.5)
Bronchitis	1 (0.5)	1 (0.5)	-	-	-	-
Nasopharyngitis	1 (0.5)	-	1 (0.5)	-	1 (0.5)	2 (1.0)
Urinary tract infection	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	-	1 (0.5)
Back pain	1 (0.5)	-	1 (0.5)	-	1 (0.5)	1 (0.5)
Cough	1 (0.5)	-	1 (0.5)	-	-	1 (0.5)
Pharyngitis	-	-	1 (0.5)	2 (1.0)	1 (0.5)	-
Pharyngolaryngeal pain	-	-	2 (1.0)	-	-	-
Upper respiratory tract infection	-	-	-	-	1 (0.5)	1 (0.5)
Contusion	-	1 (0.5)	-	-	1 (0.5)	-
Vertigo	1 (0.5)	-	-	-	2 (1.0)	-
Chest pain	1 (0.5)	-	-	-	-	-
Depression	-	-	1 (0.5)	-	-	-
Dyspnoea	-	-	1 (0.5)	-	-	-
Facial bones fracture	-	-	1 (0.5)	-	-	-
Headache	1 (0.5)	-	-	-	-	1 (0.5)
Herpes zoster	-	-	-	-	1 (0.5)	-
Lymphadenopathy	-	-	-	-	-	-
Musculoskeletal pain	-	-	1 (0.5)	-	1 (0.5)	-
Osteoarthritis	-	-	-	-	-	-
Otitis externa	-	-	1 (0.5)	-	-	-
Pulmonary oedema	1 (0.5)	-	-	-	-	1 (0.5)
Rhinitis	-	-	-	-	-	-
Skin injury	-	-	-	-	-	-
Abdominal discomfort	-	-	-	1 (0.5)	-	-
Anaemia	-	1 (0.5)	-	-	-	-

Arrhythmia	-	-	-	-	1 (0.5)	-
Asthma	-	-	-	-	1 (0.5)	-
Back injury	-	-	1 (0.5)	-	-	-
Bacterial infection	-	-	-	-	-	-
Benign prostatic hyperplasia	-	-	-	-	1 (0.5)	-
Bile duct stone	-	-	1 (0.5)	-	-	-
Bladder cancer	-	-	-	-	-	1 (0.5)
Blood pressure increased	1 (0.5)	-	-	-	-	-
Borrelia infection	-	-	-	-	-	-
Bradycardia	-	1 (0.5)	-	-	-	-
Bursitis	-	1 (0.5)	-	-	-	-
Carpal tunnel syndrome	1 (0.5)	-	-	-	-	-
Cataract operation	-	-	-	-	-	1 (0.5)
Cerebrovascular accident	-	-	-	-	-	1 (0.5)
Cholelithiasis	-	-	1 (0.5)	-	-	-
Chronic obstructive pulmonary disease	-	-	-	-	-	1 (0.5)
Conjunctivitis	-	-	-	-	-	1 (0.5)
Dental caries	-	-	-	-	1 (0.5)	-
Diabetes mellitus	-	-	-	-	-	-
Diarrhoea	-	-	-	-	-	-
Dry eye	-	-	-	-	-	-
Dyspepsia	-	-	-	-	-	-
Dyspnoea exertional	-	1 (0.5)	-	-	-	-
Eczema	1 (0.5)	-	-	-	-	-
Erysipelas	1 (0.5)	-	-	-	-	-
Eye oedema	-	-	-	-	-	-
Facial palsy	-	-	-	-	-	-
Facial paresis	-	-	-	-	-	-
Fractured coccyx	-	-	-	-	-	-
Gastric ulcer haemorrhage	-	-	-	-	-	-
Gastritis	-	-	1 (0.5)	-	-	-
Goitre	-	-	-	1 (0.5)	-	-
Gout	-	-	1 (0.5)	-	-	-
Haematoma	-	-	-	1 (0.5)	-	-
Haemorrhoids	-	1 (0.5)	-	-	-	-
Hip fracture	-	-	-	1 (0.5)	-	-
Hyperkalaemia	-	-	-	-	-	1 (0.5)
Hyperlipidaemia	1 (0.5)	-	-	-	-	-
Hypoglycaemia	-	-	-	-	-	-
Iliac vein occlusion	-	1 (0.5)	-	-	-	-
Influenza like illness	-	-	-	1 (0.5)	-	-
Ingrowing nail	-	-	-	-	-	1 (0.5)
Insomnia	-	-	-	-	-	1 (0.5)
Intervertebral disc protrusion	1 (0.5)	-	-	-	-	-
Ishaemic stroke	-	-	-	-	-	-
Jaw disorder	-	-	-	-	1 (0.5)	-
Joint injury	1 (0.5)	-	-	-	-	-
Lacrimation increased	-	-	-	-	-	-
Limb injury	-	-	-	1 (0.5)	-	-
Lower respiratory tract infection	-	-	-	-	1 (0.5)	-
Macular degeneration	-	-	-	1 (0.5)	-	-
Multiple myeloma	-	-	-	-	1 (0.5)	-
Muscle spasms	1 (0.5)	-	-	-	-	-
Musculoskeletal chest pain	-	-	-	-	-	-
Musculoskeletal stiffness	-	-	-	1 (0.5)	-	-
Myocardial infarction	-	1 (0.5)	-	-	-	-

Onychomycosis	-	1 (0.5)	-	-	-	-
Pain in extremity	-	1 (0.5)	-	-	-	-
Pancreatic neoplasm	-	-	-	-	1 (0.5)	-
Paronychia	-	-	-	1 (0.5)	-	-
Pharyngeal inflammation	1 (0.5)	-	-	-	-	-
Post procedural infection	-	-	-	-	-	-
Prostatic disorder	-	-	1 (0.5)	-	-	-
Pruritus	-	-	-	-	-	-
Pyelonephritis	-	-	-	-	-	1 (0.5)
Pyrexia	-	-	1 (0.5)	-	-	-
Rash maculo-papular	-	-	-	-	-	-
Renal pain	-	-	-	1 (0.5)	-	-
Sinobronchitis	-	-	1 (0.5)	-	-	-
Sleep apnoea syndrome	-	1 (0.5)	-	-	-	-
Spinal disorder	-	-	-	1 (0.5)	-	-
Synovial cyst	-	1 (0.5)	-	-	-	-
Tachycardia	-	-	-	-	-	1 (0.5)
Tendonitis	-	-	-	1 (0.5)	-	-
Thrombophlebitis	-	-	-	-	1 (0.5)	-
Tooth disorder	-	-	-	-	-	-
Toothache	-	-	-	1 (0.5)	-	-
Type 2 diabetes mellitus	-	-	1 (0.5)	-	-	-
Vocal cord inflammation	1 (0.5)	-	-	-	-	-
Vulvovaginal pruritus	-	-	-	-	1 (0.5)	-
Wound	-	-	-	1 (0.5)	-	-
Wrist fracture	-	-	-	-	-	-
Adverse events resulting in medically attended visit		AS50_1_4 Group N = 198	AS50_1_2 Group N = 199	Flu_ELD Group N = 200	Flu_YNG Group N = 203	
Subjects with any AE(s), n (%)		11 (5.6)	13 (6.5)	10 (5.0)	13 (6.4)	
Subjects with grade 3 AE(s)*, n (%)		1 (0.5)	4 (2.0)	1 (0.5)	1 (0.5)	
Subjects with related AE(s)**, n (%)		0 (0.0)	2 (1.0)	1 (0.5)	2 (1.0)	
Hypertension		1 (0.5)	-	4 (2.0)	-	
Bronchitis		1 (0.5)	2 (1.0)	1 (0.5)	2 (1.0)	
Nasopharyngitis		2 (1.0)	-	-	1 (0.5)	
Urinary tract infection		1 (0.5)	-	-	1 (0.5)	
Back pain		2 (1.0)	-	-	-	
Cough		-	-	-	3 (1.5)	
Pharyngitis		-	-	-	1 (0.5)	
Pharyngolaryngeal pain		-	1 (0.5)	-	2 (1.0)	
Upper respiratory tract infection		-	1 (0.5)	-	1 (0.5)	
Contusion		-	-	1 (0.5)	-	
Vertigo		-	-	-	-	
Arthralgia		-	1 (0.5)	-	1 (0.5)	
Atrial fibrillation		1 (0.5)	1 (0.5)	-	-	
Chest pain		-	1 (0.5)	-	-	
Depression		-	1 (0.5)	-	-	
Dyspnoea		-	1 (0.5)	-	-	
Facial bones fracture		-	1 (0.5)	-	-	
Headache		-	-	-	-	
Herpes zoster		-	1 (0.5)	-	-	
Lymphadenopathy		-	-	-	2 (1.0)	
Musculoskeletal pain		-	-	-	-	
Osteoarthritis		1 (0.5)	-	1 (0.5)	-	
Otitis externa		-	1 (0.5)	-	-	
Pulmonary oedema		-	-	-	-	

Rhinitis	-	-	1 (0.5)	1 (0.5)
Skin injury	-	1 (0.5)	1 (0.5)	-
Abdominal discomfort	-	-	-	-
Anaemia	-	-	-	-
Arrhythmia	-	-	-	-
Asthma	-	-	-	-
Back injury	-	-	-	-
Bacterial infection	-	-	1 (0.5)	-
Benign prostatic hyperplasia	-	-	-	-
Bile duct stone	-	-	-	-
Bladder cancer	-	-	-	-
Blood pressure increased	-	-	-	-
Borrelia infection	1 (0.5)	-	-	-
Bradycardia	-	-	-	-
Bursitis	-	-	-	-
Carpal tunnel syndrome	-	-	-	-
Cataract operation	-	-	-	-
Cerebrovascular accident	-	-	-	-
Cholelithiasis	-	-	-	-
Chronic obstructive pulmonary disease	-	-	-	-
Conjunctivitis	-	-	-	-
Dental caries	-	-	-	-
Diabetes mellitus	-	-	1 (0.5)	-
Diarrhoea	-	1 (0.5)	-	-
Dry eye	-	-	1 (0.5)	-
Dyspepsia	1 (0.5)	-	-	-
Dyspnoea exertional	-	-	-	-
Eczema	-	-	-	-
Erysipelas	-	-	-	-
Eye oedema	-	1 (0.5)	-	-
Facial palsy	1 (0.5)	-	-	-
Facial paresis	-	1 (0.5)	-	-
Fractured coccyx	-	-	-	1 (0.5)
Gastric ulcer haemorrhage	1 (0.5)	-	-	-
Gastritis	-	-	-	-
Goitre	-	-	-	-
Gout	-	-	-	-
Haematoma	-	-	-	-
Haemorrhoids	-	-	-	-
Hip fracture	-	-	-	-
Hyperkalaemia	-	-	-	-
Hyperlipidaemia	-	-	-	-
Hypoglycaemia	1 (0.5)	-	-	-
Iliac vein occlusion	-	-	-	-
Influenza like illness	-	-	-	-
Ingrowing nail	-	-	-	-
Insomnia	-	-	-	-
Intervertebral disc protrusion	-	-	-	-
Ischaemic stroke	-	1 (0.5)	-	-
Jaw disorder	-	-	-	-
Joint injury	-	-	-	-
Lacrimation increased	1 (0.5)	-	-	-
Limb injury	-	-	-	-
Lower respiratory tract infection	-	-	-	-
Macular degeneration	-	-	-	-

Multiple myeloma	-	-	-	-
Muscle spasms	-	-	-	-
Musculoskeletal chest pain	-	1 (0.5)	-	-
Musculoskeletal stiffness	-	-	-	-
Myocardial infarction	-	-	-	-
Onychomycosis	-	-	-	-
Pain in extremity	-	-	-	-
Pancreatic neoplasm	-	-	-	-
Paronychia	-	-	-	-
Pharyngeal inflammation	-	-	-	-
Post procedural infection	-	1 (0.5)	-	-
Prostatic disorder	-	-	-	-
Pruritus	1 (0.5)	-	-	-
Pyelonephritis	-	-	-	-
Pyrexia	-	-	-	-
Rash maculo-papular	-	1 (0.5)	-	-
Renal pain	-	-	-	-
Sinobronchitis	-	-	-	-
Sleep apnoea syndrome	-	-	-	-
Spinal disorder	-	-	-	-
Synovial cyst	-	-	-	-
Tachycardia	-	-	-	-
Tendonitis	-	-	-	-
Thrombophlebitis	-	-	-	-
Tooth disorder	-	1 (0.5)	-	-
Toothache	-	-	-	-
Type 2 diabetes mellitus	-	-	-	-
Vocal cord inflammation	-	-	-	-
Vulvovaginal pruritus	-	-	-	-
Wound	-	-	-	-
Wrist fracture	-	-	-	1 (0.5)

- = Adverse event absent

*Grade 3 = event that prevented normal activities

**Related = event assessed by the investigators as causally related to the study vaccination

Secondary Outcome variable(s): Number (%) of subjects with adverse events that resulted in a medically attended visit between Day 21 and Day 179 after vaccination (Total vaccinated cohort)

Adverse events resulting in medically attended visit	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198
Subjects with any AE(s), n (%)	78 (38.2)	60 (29.7)	79 (39.1)	71 (35.1)	65 (32.7)	67 (33.8)
Subjects with grade 3 AE(s)*, n (%)	18 (8.8)	11 (5.4)	13 (6.4)	13 (6.4)	10 (5.0)	12 (6.1)
Subjects with related AE(s)**, n (%)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Bronchitis	9 (4.4)	4 (2.0)	4 (2.0)	7 (3.5)	7 (3.5)	6 (3.0)
Nasopharyngitis	5 (2.5)	-	5 (2.5)	4 (2.0)	3 (1.5)	7 (3.5)
Back pain	-	6 (3.0)	5 (2.5)	3 (1.5)	4 (2.0)	-
Cough	-	2 (1.0)	3 (1.5)	4 (2.0)	-	5 (2.5)
Hypertension	6 (2.9)	3 (1.5)	-	-	5 (2.5)	4 (2.0)
Cystitis	-	2 (1.0)	-	4 (2.0)	-	-
Osteoarthritis	-	5 (2.5)	3 (1.5)	-	3 (1.5)	-
Sinusitis	-	-	-	-	-	-
Eczema	-	2 (1.0)	3 (1.5)	-	-	-
Upper respiratory tract infection	-	2 (1.0)	3 (1.5)	-	-	-
Angina pectoris	-	-	-	3 (1.5)	-	-
Gastritis	-	-	-	3 (1.5)	-	-
Pneumonia	3 (1.5)	-	-	-	-	-

Sciatica	-	-	3 (1.5)	-	-	-
Contusion	-	-	3 (1.5)	-	-	-
Depression	5 (2.5)	-	-	-	-	-
Headache	-	-	-	-	-	-
Pharyngitis	-	-	-	-	-	-
Abdominal pain upper	-	-	-	3 (1.5)	-	-
Dyspepsia	3 (1.5)	-	-	-	-	-
Dyspnoea	3 (1.5)	-	-	-	-	-
Glaucoma	-	-	-	-	-	3 (1.5)
Influenza like illness	-	-	3 (1.5)	-	-	-
Pain in extremity	-	-	-	-	3 (1.5)	-
Skin papilloma	-	-	-	3 (1.5)	-	-
Urinary tract infection	-	-	-	-	-	-
Abscess	-	2 (1.0)	-	-	-	-
Cataract operation	-	2 (1.0)	-	-	-	-
Dizziness	-	-	-	-	-	-
Hypercholesterolaemia	-	-	-	-	-	-
Musculoskeletal pain	-	2 (1.0)	-	-	-	-
Peripheral arterial occlusive disease	-	2 (1.0)	-	-	-	-
Prostatitis	-	2 (1.0)	-	-	-	-
Sleep disorder	-	-	-	-	-	-
Tooth infection	-	2 (1.0)	-	-	-	-
Viral infection	-	2 (1.0)	-	-	-	-
Adverse events resulting in medically attended visit	AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203		
Subjects with any AE(s), n (%)	67 (33.8)	69 (34.7)	69 (34.5)	62 (30.5)		
Subjects with grade 3 AE(s)*, n (%)	17 (8.6)	15 (7.5)	17 (8.5)	10 (4.9)		
Subjects with related AE(s)**, n (%)	1 (0.5)	0 (0.0)	1 (0.5)	0 (0.0)		
Bronchitis	3 (1.5)	3 (1.5)	3 (1.5)	5 (2.5)		
Nasopharyngitis	2 (1.0)	6 (3.0)	3 (1.5)	6 (3.0)		
Back pain	-	3 (1.5)	-	5 (2.5)		
Cough	3 (1.5)	4 (2.0)	-	-		
Hypertension	-	-	-	-		
Cystitis	3 (1.5)	-	3 (1.5)	5 (2.5)		
Osteoarthritis	2 (1.0)	3 (1.5)	-	-		
Sinusitis	-	4 (2.0)	4 (2.0)	-		
Eczema	2 (1.0)	-	-	-		
Upper respiratory tract infection	2 (1.0)	-	-	-		
Angina pectoris	-	3 (1.5)	-	-		
Gastritis	-	-	3 (1.5)	-		
Pneumonia	-	3 (1.5)	-	-		
Sciatica	-	3 (1.5)	-	-		
Contusion	2 (1.0)	-	-	-		
Depression	-	-	-	-		
Headache	2 (1.0)	-	3 (1.5)	-		
Pharyngitis	-	-	-	4 (2.0)		
Abdominal pain upper	-	-	-	-		
Dyspepsia	-	-	-	-		
Dyspnoea	-	-	-	-		
Glaucoma	-	-	-	-		
Influenza like illness	-	-	-	-		
Pain in extremity	-	-	-	-		
Skin papilloma	-	-	-	-		

Urinary tract infection	-	-	3 (1.5)	-
Abscess	-	-	-	-
Cataract operation	-	-	-	-
Dizziness	2 (1.0)	-	-	-
Hypercholesterolaemia	2 (1.0)	-	-	-
Musculoskeletal pain	-	-	-	-
Peripheral arterial occlusive disease	-	-	-	-
Prostatitis	-	-	-	-
Sleep disorder	2 (1.0)	-	-	-
Tooth infection	-	-	-	-
Viral infection	-	-	-	-

Counting rule applied: As there were more than 30 subjects per treatment group and > 3 groups, only the 5 most frequent events in each treatment group are to be listed.

-: Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 5 most frequent events for that group

*Grade 3 = event that prevented normal activities

**Related = event assessed by the investigator as causally related to the study vaccination

Safety results: Number (%) of subjects with unsolicited adverse events within a 21-day follow-up period (Total Vaccinated cohort)

Most frequent adverse events –On-Therapy (occurring within Days 0-20 following vaccination)	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198
Subjects with any AE(s), n (%)	41 (20.1)	32 (15.8)	51 (25.2)	39 (19.3)	34 (17.1)	42 (21.2)
Subjects with grade 3 AE(s)*, n (%)	1(0.5)	3(1.5)	8(4.0)	3(1.5)	0(0.0)	6(3.0)
Subjects with related AE(s)**, n (%)	5(2.5)	7(3.5)	15(7.4)	6(3.0)	13(6.5)	13(6.6)
Nasopharyngitis	9 (4.4)	4 (2.0)	7 (3.5)	5 (2.5)	7 (3.5)	8 (4.0)
Influenza like illness	-	2 (1.0)	2 (1.0)	3 (1.5)	2 (1.0)	-
Pharyngolaryngeal pain	2 (1.0)	2 (1.0)	3 (1.5)	2 (1.0)	-	-
Injection site pruritus	-	1 (0.5)	4 (2.0)	-	3 (1.5)	-
Pruritus	-	1 (0.5)	4 (2.0)	-	2 (1.0)	-
Cough	3 (1.5)	1 (0.5)	-	2 (1.0)	-	-
Back pain	2 (1.0)	1 (0.5)	-	2 (1.0)	-	-
Headache	3 (1.5)	-	-	2 (1.0)	-	-
Pain in extremity	-	1 (0.5)	-	-	-	3 (1.5)
Upper respiratory tract infection	-	1 (0.5)	-	-	-	3 (1.5)
Abdominal discomfort	-	1 (0.5)	-	2 (1.0)	-	-
Diarrhoea	-	1 (0.5)	2 (1.0)	-	-	-
Dizziness	2 (1.0)	1 (0.5)	-	-	-	-
Dyspnoea	-	1 (0.5)	2 (1.0)	-	-	-
Hypertension	-	-	-	-	-	3 (1.5)
Oral herpes	-	1 (0.5)	2 (1.0)	-	-	-
Vertigo	-	1 (0.5)	-	-	2 (1.0)	-
Bronchitis	-	2 (1.0)	-	-	-	-
Dyspepsia	-	1 (0.5)	-	-	-	-
Rhinitis	-	1 (0.5)	-	-	-	-
Urinary tract infection	-	1 (0.5)	-	-	-	-
Arthralgia	-	1 (0.5)	-	-	-	-
Muscle spasms	-	1 (0.5)	-	-	-	-
Anaemia	-	1 (0.5)	-	-	-	-
Bradycardia	-	1 (0.5)	-	-	-	-
Myocardial infarction	-	1 (0.5)	-	-	-	-
Haemorrhoids	-	1 (0.5)	-	-	-	-
Asthenia	-	1 (0.5)	-	-	-	-
Chills	-	1 (0.5)	-	-	-	-

Feeling cold	-	1 (0.5)	-	-	-	-
Onychomycosis	-	1 (0.5)	-	-	-	-
Back injury	-	1 (0.5)	-	-	-	-
Contusion	-	1 (0.5)	-	-	-	-
Bursitis	-	1 (0.5)	-	-	-	-
Synovial cyst	-	1 (0.5)	-	-	-	-
Hypoaesthesia	-	1 (0.5)	-	-	-	-
Sleep disorder	-	1 (0.5)	-	-	-	-
Dyspnoea exertional	-	1 (0.5)	-	-	-	-
Productive cough	-	1 (0.5)	-	-	-	-
Sleep apnoea syndrome	-	1 (0.5)	-	-	-	-
Erythema	-	1 (0.5)	-	-	-	-
Hyperhidrosis	-	1 (0.5)	-	-	-	-
Tooth extraction	-	1 (0.5)	-	-	-	-
Iliac vein occlusion	-	1 (0.5)	-	-	-	-
Paraesthesia	-	-	2 (1.0)	-	-	-
Pharyngitis	-	-	-	2 (1.0)	-	-
Abdominal pain upper	-	-	-	2 (1.0)	-	-
Injection site warmth	-	-	-	-	2 (1.0)	-
Insomnia	-	-	-	-	-	3 (1.5)
Nausea	-	-	-	-	-	-
Fatigue	-	-	-	-	-	-
Lymphadenopathy	-	-	-	-	-	-
Toothache	-	-	-	-	-	-
Pyrexia	-	-	-	-	-	-
Most frequent adverse events–On-Therapy (occurring within Days 0-20 following vaccination)	AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203		
Subjects with any AE(s), n (%)	34 (17.2)	43 (21.6)	27 (13.5)	44 (21.7)		
Subjects with grade 3 AE(s)*, n (%)	1(0.5)	6(3.0)	1(0.5)	3(1.5)		
Subjects with related AE(s)**, n (%)	8(4.0)	18(9.0)	6(3.0)	13(6.4)		
Nasopharyngitis	6 (3.0)	7 (3.5)	2 (1.0)	11 (5.4)		
Influenza like illness	-	-	-	-		
Pharyngolaryngeal pain	-	-	-	5 (2.5)		
Injection site pruritus	2 (1.0)	6 (3.0)	-	-		
Pruritus	-	-	-	-		
Cough	-	-	-	4 (2.0)		
Back pain	3 (1.5)	-	-	-		
Headache	-	-	2 (1.0)	3 (1.5)		
Pain in extremity	-	3 (1.5)	-	-		
Upper respiratory tract infection	-	-	-	2 (1.0)		
Abdominal discomfort	-	-	-	-		
Diarrhoea	-	3 (1.5)	3 (1.5)	2 (1.0)		
Dizziness	-	3 (1.5)	2 (1.0)	-		
Dyspnoea	-	-	-	-		
Hypertension	2 (1.0)	-	4 (2.0)	-		
Oral herpes	-	-	-	-		
Vertigo	-	-	-	-		
Bronchitis	-	-	-	2 (1.0)		
Dyspepsia	2 (1.0)	-	-	-		
Rhinitis	-	-	2 (1.0)	-		
Urinary tract infection	-	-	-	-		
Arthralgia	-	-	-	-		
Muscle spasms	-	-	-	-		

Anaemia	-	-	-	-
Bradycardia	-	-	-	-
Myocardial infarction	-	-	-	-
Haemorrhoids	-	-	-	-
Asthenia	-	-	-	-
Chills	-	-	-	-
Feeling cold	-	-	-	-
Onychomycosis	-	-	-	-
Back injury	-	-	-	-
Contusion	-	-	-	-
Bursitis	-	-	-	-
Synovial cyst	-	-	-	-
Hypoaesthesia	-	-	-	-
Sleep disorder	-	-	-	-
Dyspnoea exertional	-	-	-	-
Productive cough	-	-	-	-
Sleep apnoea syndrome	-	-	-	-
Erythema	-	-	-	-
Hyperhidrosis	-	-	-	-
Tooth extraction	-	-	-	-
Iliac vein occlusion	-	-	-	-
Paraesthesia	-	-	-	-
Pharyngitis	-	-	-	-
Abdominal pain upper	-	-	-	-
Injection site warmth	-	-	-	-
Insomnia	-	-	-	-
Nausea	-	-	2 (1.0)	-
Fatigue	-	-	2 (1.0)	-
Lymphadenopathy	-	-	-	2 (1.0)
Toothache	-	-	-	2 (1.0)
Pyrexia	-	-	-	2 (1.0)

Counting rule applied: As there were more than 30 subjects per treatment group and > 3 groups, only the 5 most frequent events in each treatment group are to be listed.

-: Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 5 most frequent events for that group

*Grade 3 = event that prevented normal activities

**Related = event assessed by the investigators as causally related to the study vaccination

Safety results: Number (%) of subjects with serious adverse events reported between Day 0 and Day 20 (Total Vaccinated cohort)

Serious adverse event, n (%) [n considered by the investigator to be related to study medication]

All SAEs	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198
Subjects with any SAE(s), n (%) [n assessed by investigators as related]	0 (0.0) [0]	3 (1.5) [0]	2 (1.0) [0]	2 (1.0) [0]	2 (1.0) [0]	4 (2.0) [0]
Atrial fibrillation	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Bile duct stone	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Bladder cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Bradycardia	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cerebrovascular accident	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Chest pain	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cholelithiasis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Chronic obstructive pulmonary disease	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Dyspnoea	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

Dyspnoea exertional	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Facial bones fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastric ulcer haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Goitre	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Gout	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hip fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Ischaemic stroke	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Multiple myeloma	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Musculoskeletal chest pain	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Myocardial infarction	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pain in extremity	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pancreatic neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Post procedural infection	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pyelonephritis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Skin injury	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Fatal SAEs	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198
Subjects with fatal SAE(s), n (%) [n assessed by investigators as related]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Pancreatic neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
All SAEs		AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203	
Subjects with any SAE(s), n (%) [n assessed by investigators as related]		2 (1.0) [0]	4 (2.0) [1]	0 (0.0) [0]	0 (0.0) [0]	
Atrial fibrillation		1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Bile duct stone		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Bladder cancer		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Bradycardia		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Cerebrovascular accident		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Chest pain		0 (0.0) [0]	1 (0.5) [1]	0 (0.0) [0]	0 (0.0) [0]	
Cholelithiasis		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Chronic obstructive pulmonary disease		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Dyspnoea		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Dyspnoea exertional		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Facial bones fracture		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Gastric ulcer haemorrhage		1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Goitre		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Gout		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Hip fracture		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Ischaemic stroke		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Multiple myeloma		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Musculoskeletal chest pain		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Myocardial infarction		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Pain in extremity		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Pancreatic neoplasm		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Post procedural infection		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Pyelonephritis		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	
Skin injury		0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	
Fatal SAEs		AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203	
Subjects with fatal SAE(s), n (%) [n assessed by		0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	

investigators as related]						
Pancreatic neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Safety results: Number (%) of subjects with SAEs between Day 21 and Day 179 (Total Vaccinated cohort)						
Serious adverse event, n (%) [n considered by the investigator to be related to study medication]						
All SAEs	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198
Subjects with any SAE(s), n (%) [n assessed by investigators as related]	18 (8.8) [0]	9 (4.5) [0]	5 (2.5) [0]	8 (4.0) [0]	9 (4.5) [0]	10 (5.1) [0]
Osteoarthritis	1 (0.5) [0]	2 (1.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Prostate cancer	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	1 (0.5) [0]
Angina pectoris	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Arrhythmia	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Chest pain	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cardiac failure	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Myocardial infarction	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pancreatitis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Peripheral arterial occlusive disease	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Abdominal pain	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Angina unstable	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Atrial fibrillation	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Cellulitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Depression	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Haematoma	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Left ventricular failure	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pneumonia	2 (1.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Syncope	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Upper limb fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	1 (0.5) [0]
Uterine cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Wrist fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Abdominal adhesions	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Abdominal pain upper	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Anaemia	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Atrioventricular block first degree	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Benign salivary gland neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Bifascicular block	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Biliary colic	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Bleeding varicose vein	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Breast cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Carotid artery stenosis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Cerebral haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cerebral infarction	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cervical vertebral fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cholecystitis chronic	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cholelithiasis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Chronic myeloid leukaemia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Chronic myelomonocytic leukaemia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Chronic obstructive pulmonary disease	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Clavicle fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Colon cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Coronary artery disease	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Coronary artery stenosis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cystitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Deep vein thrombosis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

Dehydration	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Diverticulitis	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Dyspnoea	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Emphysema	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Erysipelas	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Food poisoning	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gangrene	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastric ulcer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastritis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastroenteritis norovirus	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastrointestinal haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Glaucoma	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gout	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hand fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Headache	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Herpes zoster	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hydronephrosis	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertension	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertensive cardiomyopathy	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertensive crisis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypoglycaemia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypovolaemic shock	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Ileus	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Incisional hernia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Intervertebral disc protrusion	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Jaw fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Metastases to central nervous system	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Multiple fractures	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Nasal septum deviation	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Nephrolithiasis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Neuritis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Osteoporotic fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Panic attack	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pelvic fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Postmenopausal haemorrhage	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Prostate cancer metastatic	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Prostatic adenoma	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Renal failure	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Reversible ischaemic neurological deficit	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Sick sinus syndrome	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Staphylococcal sepsis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Syncope vasovagal	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Thyroid neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Transient ischaemic attack	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Ulcerative keratitis	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Upper respiratory tract infection	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Urinary tract infection	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Urosepsis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Varicose vein	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Vestibular disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Vestibular neuronitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Fatal SAEs	AS03 1/4 Group N = 204	AS03 1/2 Group N = 202	AS03 1/1 Group N = 202	AS25 1/4 Group N = 202	AS25 1/2 Group N = 199	AS25 1/1 Group N = 198

Subjects with fatal SAE(s), n (%) [n assessed by investigators as related]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Cerebral haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cervical vertebral fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastrointestinal haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Metastases to central nervous system	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Pneumonia	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
All SAEs	AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203		
Subjects with any SAE(s), n (%) [n assessed by investigators as related]	16 (8.1) [0]	19 (9.5) [0]	15 (7.5) [1]	3 (1.5) [0]		
Osteoarthritis	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Prostate cancer	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Angina pectoris	0 (0.0) [0]	3 (1.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Arrhythmia	1 (0.5) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Chest pain	1 (0.5) [0]	2 (1.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cardiac failure	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Myocardial infarction	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Pancreatitis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Peripheral arterial occlusive disease	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Abdominal pain	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Angina unstable	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Atrial fibrillation	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cellulitis	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Depression	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Haematoma	0 (0.0) [0]	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]		
Left ventricular failure	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Pneumonia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Syncope	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Upper limb fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Uterine cancer	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Wrist fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Abdominal adhesions	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Abdominal pain upper	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Anaemia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Atrioventricular block first degree	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Benign salivary gland neoplasm	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Bifascicular block	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Biliary colic	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Bleeding varicose vein	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Breast cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Carotid artery stenosis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cerebral haemorrhage	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cerebral infarction	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cervical vertebral fracture	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cholecystitis chronic	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Cholelithiasis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Chronic myeloid leukaemia	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Chronic myelomonocytic leukaemia	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [1]	0 (0.0) [0]		
Chronic obstructive pulmonary disease	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]		
Clavicle fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]		
Colon cancer	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		
Coronary artery disease	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]		

Coronary artery stenosis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cystitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Deep vein thrombosis	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Dehydration	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Diverticulitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Dyspnoea	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Emphysema	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Erysipelas	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Food poisoning	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gangrene	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastric ulcer	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Gastritis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Gastroenteritis norovirus	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastrointestinal haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Glaucoma	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Gout	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hand fracture	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Headache	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Herpes zoster	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Hydronephrosis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertension	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertensive cardiomyopathy	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertensive crisis	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypoglycaemia	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Hypovolaemic shock	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Ileus	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Incisional hernia	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Intervertebral disc protrusion	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Jaw fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Metastases to central nervous system	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Multiple fractures	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Nasal septum deviation	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Nephrolithiasis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Neuritis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Osteoporotic fracture	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Panic attack	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Pelvic fracture	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Postmenopausal haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Prostate cancer metastatic	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Prostatic adenoma	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Renal failure	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Reversible ischaemic neurological deficit	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Sick sinus syndrome	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Staphylococcal sepsis	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Syncope vasovagal	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Thyroid neoplasm	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Transient ischaemic attack	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Ulcerative keratitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Upper respiratory tract infection	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Urinary tract infection	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]
Urosepsis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Varicose vein	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Vestibular disorder	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Vestibular neuronitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

Fatal SAEs	AS50 1/4 Group N = 198	AS50 1/2 Group N = 199	Flu_Eld Group N = 200	Flu_Yng Group N = 203
Subjects with fatal SAE(s), n (%) [n assessed by investigators as related]	0 (0.0) [0]	2 (1.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cerebral haemorrhage	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Cervical vertebral fracture	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Gastrointestinal haemorrhage	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Metastases to central nervous system	0 (0.0) [0]	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Pneumonia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

Conclusion: At Day 21 after vaccination, HI antibody titers were at least 78.5, 263.3 and 147.1 against the A/Solomon Islands, A/Wisconsin and B/Malaysia vaccine strains, respectively in subjects receiving Flu-1 vaccine (various formulations). At the same time point, HI antibody titers were at least 59.6, 186.7 and 153.0 against the A/Solomon Islands, A/Wisconsin and B/Malaysia vaccine strains, respectively in subjects receiving Flu-2 vaccine.

During the 21-day post-vaccination period, at least one unsolicited AE was reported by 41 (20.1%), 32 (15.8%), 51 (25.2%), 39 (19.3%), 34 (17.1%), 42 (21.2%), 34 (17.2%), 43 (21.6%), 27 (13.5%) and 44 (21.7%) subjects in the AS03 1/4, AS03 1/2, AS03 1/1, AS25 1/4, AS25 1/2, AS25 1/1, AS50 1/4, AS50 1/2, Flu_Eld and Flu_Yng groups, respectively.

During that period, SAEs were reported in 3 (1.5%), 2 (1.0%), 2 (1.0%), 2 (1.0%), 4 (2.0%), 2 (1.0%) and 4 (2.0%) subjects in the AS03 1/2, AS03 1/1, AS25 1/4, AS25 1/2, AS25 1/1, AS50 1/4 and AS50 1/2 groups, respectively; during that study phase, 1 fatal SAE was reported in 1 subject from the AS25 1/2 Group.

Between Day 21 and Day 179, SAEs were reported by 18 (8.8%), 9 (4.5%), 5 (2.5%), 8 (4.0%), 9 (4.5%), 10 (5.1%), 16 (8.1%), 19 (9.5%), 15 (7.5%) and 3 (1.5%) subjects in the AS03 1/4, AS03 1/2, AS03 1/1, AS25 1/4, AS25 1/2, AS25 1/1, AS50 1/4 and AS50 1/2, Flu_Eld and Flu_Yng groups, respectively; fatal SAEs were reported in 4 subjects, 1 subject each in the AS03 1/4 Group & the AS25 1/4 Group and 2 subjects in the AS50 1/2 Group.

All the SAEs reported during the whole course of the study were assessed by the investigators as not related to the study vaccination.

Date updated: 10-July-2014